+ All Categories
Home > Documents > OIS@AAO October 16th, 2014

OIS@AAO October 16th, 2014

Date post: 06-Apr-2016
Category:
Upload: ibf-conferences
View: 229 times
Download: 4 times
Share this document with a friend
Description:
The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies.
Popular Tags:
74
WORKBOOK WWW.OIS.NET 2014 OCTOBER 16 CHICAGO, IL SUMMIT WORKBOOK
Transcript
Page 1: OIS@AAO October 16th, 2014

WO

RK

BO

OK

W W W. O I S . N E T

2014OCTOBER 16

CHICAGO, IL

SUMMITWORKBOOK

Page 2: OIS@AAO October 16th, 2014

2014 SPONSORS

EXCLUSIVE

PREMIER

MAJOR

STRATEGIC

SUPPORTING

FOUNDING

PAN PTICA

Page 3: OIS@AAO October 16th, 2014

3

OIS CHAIRMANEmmett T. Cunningham Jr.

MD, PhD, MPHPartner

Clarus Ventures

OIS CO-CHAIRMANGilbert H. Kliman, MD

Managing DirectorInterWest Partners

OIS CO-CHAIRMANWilliam J. Link, PhD

Managing DirectorVersant Ventures

The mission of OIS is to support and drive innovation by facilitating meaningful interactions and business partnerships between CEOs of private companies, investors, industry executives, physicians and academic scientists in the ophthalmic space.

Thirty-three emerging drug, device and digital ophthalmology companies were selected to present in the morning. The program will then feature a plenary talk at lunch from the recently appointed head of Alcon, Jeff George, followed by the 2014 OIS Innovator Award Presentation. The rest of the afternoon will include timely and topical panel discussions around the FDA, funding trends, going public and industry consolidation. We hope you enjoy the rapid-fire presentations, interactive panels and most importantly the networking.

On behalf of the OIS Advisory Board, sponsors and producers, we are pleased to have your participation in what is now a bi-annual industry tradition. Stay on the lookout for future OIS podcasts and other new media content to keep you up to date on what’s trending in ophthalmology innovation.

Sincerely,

Welcome to the 6th AnnualOphthalmology Innovation Summit @ AAO!

Page 4: OIS@AAO October 16th, 2014

4

G

ENER

AL

INFO

RMAT

ION ABOUT OIS

WIFI

NETWORKING LOUNGE

SOCIAL MEDIA

FOOD FUNCTIONS

HELP DESK

SUMMIT PROGRAM

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. OIS addresses key issues, both hurdles and opportunities while showcasing the most promising private ophthalmic companies.

For your convenience, OIS@AAO is providing complimentary wireless access in the meeting area.

SSID/Name: HILTON WEBPassword: ALPHAEON (Case Sensitive)

The Networking Lounge is located on fourth floor in the Upper Exhibit Hall, just a few steps down from the Ballroom Foyer. There is space for scheduled for sporadic meetings. Schedule a meeting with fellow attendees through the OIS mobile APP.

Twitter: @OISTWEETS #OISAAOLinkedin: Ophthalmology Innovation SummitGoogle+: Ophthalmologysummit

The luncheon will take place outside of the Grand/State Ballroom in the West Lounge pre-function space.

Breakfast, Cocktail Reception and all Networking Breaks will take place on the fourth floor in the Upper Exhibit Hall, just a few steps down from the West Lounge pre-function space.

Have a question or need help with anything during OIS? Stop by the Help Desk to get the answers you need. The Help Desk is located outside of the Grand/State Ballroom in the West Lounge pre-function space and is available to you from 6:30am to 5:30pm.

General Session programming will take place in the Grand/State Ballroom on the fourth floor of the Palmer House Hilton.

Sponsored By:

Page 5: OIS@AAO October 16th, 2014

5

To enhance your networking experience, there is a mobile APP for summit attendees. The OIS@AAO app provides the perfect opportunity for you to easily connect with other attendees and speakers.

Some highlights of the APP include:

1. Attendees - view profiles for all attendees, participants and sponsors2. Messages - send and receive private messages with other attendees 3. Meetings - schedule on-site meetings with attendees throughout the day4. Agenda - view an overview of the programming in the agenda at-a-glance or explore topics

and speakers in the detailed agenda5. Speaker Bios - read background details on all participants6. Sponsor Profiles - view company overviews for all sponsors7. Slide Deck Viewing - all PowerPoint presentations are available for view under the

“Presentations” tab8. Surveys - help us to continue to improve the summit and share your feedback. There are

surveys to rate each session located within the detailed agenda.9. We have an exciting new feature in the app exclusively for physicians which gives you access

to the “ShoutMD” social networking platform, compliments of ALPHAEON. Be sure to check it out and create an account. There will also be ALPHAEON staff available in the exhibit hall to help you sign up.

To download the OIS Mobile APP, visit the APP Store or GooglePlay and search for “OIS”. Please refer to the email entitled “Welcome to The Ophthalmology Innovation Summit @AAO” for your login details.

In the OIS@AAO Mobile APP there is a tab titled “Industry Survey.” OIS is looking for feedback from the community to keep up-to-date on what is trending in ophthalmology.

Please make sure to put your mobile devices on silent or vibrate mode during sessions. Do not answer your phone in the meeting room, please go outside to take any calls.

All PowerPoint presentations are available in the OIS Mobile APP. Post-summit video presentations will be available at www.ois.net.

Please bring any articles found to the OIS@AAO Help Desk located outside of the Grand/State Ballroom.

OIS@AAO MOBILE APP

DOWNLOAD THE OIS MOBILE APP

INDUSTRY SURVEY

MOBILE PHONES

SUMMIT CONTENT/PRESENTATIONS

LOST AND FOUND

IPHONE IPAD ANDROID

GEN

ERAL IN

FORM

ATION

Page 6: OIS@AAO October 16th, 2014

6

6:30 - 7:30 AM REGISTRATION CHECK-IN & BREAKFAST

7:30 - 7:45 AM WELCOME & CHAIRMAN’S OPENING REMARKS

7:45 - 9:37 AM BIOPHARMA COMPANY SHOWCASE

7:45 - 7:53 AM ALLYSTA PHARMACEUTICALS

CO-MODERATORS

Allysta Pharmaceuticals, based in the San Francisco Bay Area, is engaged in developing innovative new treatments for serious eye diseases. Allysta is devel-oping Aly1337, a novel small molecule multikinase inhibitor discovered by D. Western Therapeutics Institute (Nagoya, Japan) targeting the trabecular meshwork for treatment of glaucoma.

Hosted By:A

GEN

DA

Emmett T. Cunningham Jr.MD, PhD, MPH

Partner - Clarus VenturesSee bio on page 32

Robert DempseyVice President & Business Unit Head

Shire OphthalmicsSee bio on page 32

Calvin W. Roberts, MDExecutive Vice President & CMO

Bausch + LombSee bio on page 52

Henry Hsu, MDFounder & CEO

See bio on page 40

2014 - Year In Review

The past year in ophthalmology has been filled with financings, scientific breakthroughs, FDA approvals, M&A deals and IPOs. OIS Founding Chairman, Emmett Cunningham Jr., MD, will walk attendees through the significant points throughout the year.

7:53 - 8:01 AM AERIE PHARMACEUTICALS

Aerie is a clinical-stage pharmaceutical company with a focus on glaucoma therapies. Aerie com-menced two Phase 3 registration trials in the US for triple-action Rhopressa™ named “Rocket 1” and “Rocket 2, a third Phase 3 safety trial, named “Rocket 3,” in Canada and a Phase 2b clinical trial for quadruple-action Roclatan™.

Vicente Anido Jr., PhDCEO

See bio on page 26

Page 7: OIS@AAO October 16th, 2014

7

8:01 - 8:09 AM ONL THERAPEUTICS

ONL Therapeutics preserves vision through the pro-tection of photoreceptors from retinal disease. ONL is developing ONL-101, a small injectable peptide that blocks photoreceptor apoptosis. Initial develop-ment targets retinal detachment with a neoadjuvant therapy at time of diagnosis and prior to surgery. Further development will protect photoreceptors until the disease is stabilized. John Freshley

CEO

See bio on page 36

8:09 - 8:17 AM KALA PHARMACEUTICALS

Kala Pharmaceuticals, Inc. is advancing innova-tive nanotechnology-based treatments for ocular diseases with significant unmet needs in both front and back of the eye. Kala leverages the company’s proprietary Mucus Penetrating Particle platform tech-nology to develop topical ophthalmic formulations that enhance ocular tissue exposure by facilitating penetration through the mucus layer. Charlie McDermott

Interim President & CBO

See bio on page 44

8:17 - 8:25 AM MC2 BIOTEK GROUP

The privately held MC2 Biotek is using its unique and patented oil-in-water dispersion - PAD™ Tech-nology - in the ophthalmic and dermatological fields. PAD™ Technology enables release of the full potential of API’s and is the basis for comfortable and patented topical drugs that will improve patient compliance and clinical benefits.

Jesper J. LangePresident & Co-Founder

See bio on page 42

AG

END

A

8:25 - 8:33 AM NOVALIQ GMBH

Novaliq GmbH, based in Heidelberg, is a drug delivery company that is developing a superior gen-eration of innovative ocular formulations for poorly soluble drugs. The patented ocular formulations are based on semifluorinated alkanes (SFAs), which can be easily applied in the form of topical eye drops.

Bernhard GüntherCEO

See bio on page 38

Page 8: OIS@AAO October 16th, 2014
Page 9: OIS@AAO October 16th, 2014

9

8:33 - 8:41 AM MOBIUS THERAPEUTICS

Mobius Therapeutics™ believes that retasking of molecules is more efficient than drug discovery. Standard of care indications creates NDA’s with less burdensome provisions. The resulting entity creates 6 products in multiple subspecialties. Revenues fund new solutions to existing problems for evolving prod-ucts and procedures.

Ed TimmPresident & CEO

See bio on page 54

8:41 - 8:49 AM GRAYBUG

GrayBug has developed a technology to reduce the frequency of treatment injections to every 4 to 6 months, reducing risks associated with repeated intraocular injections. In addition, GrayBug is ap-plying its novel technology to a lead compound that blocks both key pathways of neovascularization in w-AMD, VEGF and PDGF.

Michael O’RourkePresident & CEO

See bio on page 48

8:49 - 8:57 AM AVALANCHE BIOTECHNOLOGIES

Avalanche, a clinical-stage biotechnology company, discovers and develops novel gene therapies to treat sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular Bio-Factory™, Avalanche provides long-term benefits or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administra-tion in the eye. Thomas W. Chalberg, PhD

Founder & CEO

See bio on page 30

AG

END

A

8:57 - 9:05 AM ALLEGRO OPHTHALMICS

Allegro quickly, safely and cost-effectively bring to market new and improved treatment options for the leading causes of blindness. In only four years, Alle-gro has progressed Luminate® from drug discovery, to establishing safety and initial efficacy in both an-imals and human patients, to phase 2 clinical trials in DME and vitreomacular traction.

Vicken Karageozian, MDCo-Founder & CTO

See bio on page 40

Page 10: OIS@AAO October 16th, 2014

10

9:05 - 9:13 AM TRANSLATUM MEDICUS

Translatum Medicus inc (TMi) de-risks and acceler-ates drug development for dry Age Related Mac-ular Degeneration. TMi’s technologies include a pre-clinical model that mimics advanced dry AMD and aligns with clinical trial endpoints, and TMi-018, that dose-dependently protects against RPE loss. TMi-018 is safe in clinical studies for non-oph-thalmic indications. Shelley Boyd, MD, FRCSC

President & CSO

See bio on page 28

9:13 - 9:21 AM OPHTHOTECH

Ophthotech is a biopharmaceutical company spe-cializing in the development of novel therapeutics to treat diseases of the eye, with a focus on devel-oping innovative therapies for age-related macular degeneration. Ophthotech’s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with an-ti-VEGF drugs. David R. Guyer, MD

CEO

See bio on page 38

9:21 - 9:29 AM PANOPTES

Panoptes is a privately-held biotech company fo-cused on developing small molecule based thera-pies to treat severe eye diseases. The Panoptes team is developing a focused portfolio of high-perfor-mance small molecule products, with its lead clinical candidate PP-001 in preclinical development for uveitis, followed by dry eye disease and viral con-junctivitis. Franz Obermayr, PhD

Co-Founder & CEO

See bio on page 48

9:29 - 9:37 AM XOMA

XOMA’s innovative products candidates are a result of its focus on allosteric modulation, offering oppor-tunities to develop new classes of therapeutic anti-bodies. XOMA is developing its lead product gevoki-zumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program in non-infectious uveitis, and ongoing studies in other IL-1-mediated diseases. Paul Rubin, MD

CMO

See bio on page 52

AG

END

A

Page 11: OIS@AAO October 16th, 2014

The Ophthalmology Innovation Summit at AAO

PROUD TO BE A PREMIER SPONSOR OF

Page 12: OIS@AAO October 16th, 2014

12

9:37 - 10:07 AM NETWORKING BREAK

10:07 - 11:51 AM DEVICE, DELIVERY & DIAGNOSTICS COMPANY SHOWCASE

CO-MODERATORS

Laurent AttiasHead, Global Commercial Strategy

AlconSee bio on page 26

Jane RadyDivisional Vice President Business DevelopmentAbbott Medical Optics

See bio on page 50

10:07 - 10:15 AM TEARSCIENCE

TearScience® has pioneered ophthalmic procedures and devices that identify, diagnose and treat evap-orative dry eye. The TearScience® in-office Dry Eye Solution includes the SPEED© Dry Eye Question-naire, Korb MGE™, LipiView® Ocular Surface In-terferometer and LipiFlow® treatment device along with a simplified implementation plan, practice marketing tools, and proven procedure support. Tim Willis

Co-Founder & CEO

See bio on page 54

10:15 - 10:23 AM WAVETEC VISION SYSTEMS

WaveTec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons. Our revolutionary ORA System® provides intraoperative refractive information to ophthalmologists worldwide, allowing them to deliv-er the best possible vision for their cataract patients.

Thomas G. FrinziPresident & CEO

See bio on page 36

10:23 - 10:31 AM POWERVISION

PowerVision, Inc. has developed a proprietary flu-id-controlled accommodating intraocular lens (IOL) technology designed to restore youthful vision to millions of middle aged or elderly individuals. The Company has proven in recent clinical trials that it can deliver clear near, intermediate and distance vision with its fully injectable accommodating device.

Barry CheskinPresident & CEO

See bio on page 32

AG

END

A

Page 13: OIS@AAO October 16th, 2014

13

10:31 - 10:39 AM AVEDRO

Avedro is a privately held medical device and pharmaceutical company developing corneal cross-linking, a non-invasive treatment for refractive disorders and certain pathologies. Avedro sells in 62 countries and recently submitted an NDA to the FDA. Avedro is also developing, Photorefractive Intrastromal Cross-Linking (PiXL™), for post-cataract ametropia and refractive correction. David Muller, PhD

President & CEO

See bio on page 46

10:39 - 10:47 AM IMPLANDATA OPHTHALMIC PRODUCTS GMBH

Implandata Ophthalmic Products, an ophthalmic device and digital health company, offers a solution for improved glaucoma care. Implandata‘s implant-able intraocular pressure sensors, it is possible to measure circadian intraocular pressure (IOP) vari-ations and IOP at home. Digital health integration will increase quality of care dramatically,resulting in improved therapy and better disease outcome. Max G. Ostermeier, MBA

Co-Founder & General Manager

See bio on page 48

Implandata Ophthalmic Products GmbH

10:47 - 10:55 AM INNFOCUS

InnFocus MicroShunt ™ addresses the largest glau-coma patient segment and has achieved mean post op IOP’s below 14 mm Hg, and 80% med reduc-tion. IOP reduction at 3 months similar to 3 year.

By 12/31/14, over 20 doctors will have treated over 150 patients, followed for up to 3 years.

Russell TrenaryPresident & CEO

See bio on page 54

10:55 - 11:03 AM IOPTIMA

IOPtima Ltd., a Bio-Light company (BOLT:TASE) is a developer of laser-assisted surgical ophthalmic devices. The company’s flagship product, the IOPti-mate™, is a surgical system to treat Glaucoma, uti-lizing a CO2 laser technology to significantly reduce internal eye pressure (“IOP”), by restoring the natural fluid percolation without penetrating into the eye.

Ronen CastroCEO

See bio on page 30

AG

END

A

Page 14: OIS@AAO October 16th, 2014

14

11:03 - 11:11 AM I-OPTICS

i-Optics pioneers smart and superior eye diagnosis solutions that are affordable, fast and user-friend-ly for care providers worldwide. Their innovations include: Cassini – A first-of-its-kind Corneal Shape Analyzer, EasyScan – A breakthrough, zero-dilation retinal imaging system to diagnose retinal diseas-es, and EyePrevent –An effective and cost-efficient retinal disease screening service. Jeroen Cammeraat

CEO

See bio on page 30

11:11 - 11:19 AM NEUROTECH

Neurotech Pharmaceutical’s core technology, Encap-sulated Cell Therapy (ECT), is a proprietary first-in-class drug delivery platform for the treatment of chronic eye diseases. The ECT implant enables con-tinuous immune-privileged production and delivery of therapeutic proteins, derived from a customized cell line, for at least two years to the posterior segment.

Quinton OswaldPresident & CEO

See bio on page 50

11:19 - 11:27 AM FORSIGHT VISION5

ForSight VISION5 is focused on developing non-in-vasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy.

John MaroneyCEO

See bio on page 44

11:27 - 11:35 AM MATI THERAPEUTICS

Mati is developing a sustained drug delivery plat-form to treat various ocular diseases including glau-coma using punctal plugs as an anchoring device to deliver drugs to the tear film of the eye. The lead product is completing Phase II trials using latano-prost with plans to start Phase III in 2015.

Robert ButchofskyFounder & CEO

See bio on page 30

AG

END

A

Page 15: OIS@AAO October 16th, 2014

15

11:35 - 11:43 AM OCULAR THERAPEUTIX

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commer-cialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The Company is currently evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved.

Amarpreet Sawhney, PhDPresident & CEO

See bio on page 52

11:43 - 11:51 AM ALIMERA SCIENCES

Alimera Sciences is a pharmaceutical company focused on diseases affecting the retina. Its prod-uct, ILUVIEN® (fluocinolone acetonide intravitreal implant) has received marketing authorization for chronic diabetic macular edema considered insuffi-ciently responsive to available therapies in Austria, Denmark, France, Italy, Norway, Portugal and Spain, and has been launched in Germany and the UK. Dan Myers

President & CEO

See bio on page 46

11:51 - 12:21 PM DIGITAL OPHTHALMOLOGY SHOWCASE

MODERATED BY:

Gilbert H. Kliman, MDManaging DirectorInterWest Partners

See bio on page 42

AG

END

A

11:51 - 11:56 AM CHECKEDUP

CheckedUp empowers patients to take a more active role in their health. Through the app, patients can learn about treatment options, prepare for proce-dures, request more information from their doctor and receive medication and appointment reminders, as well as coupons and vouchers from the conve-nience of their computer, tablet or phone.

Richard M. Awdeh, MDFounder & CEO

See bio on page 28

Page 16: OIS@AAO October 16th, 2014

300 Brickstone Square | Andover, MA 01810 | (978) 494-4899

www.oraclinical.com/ascrs

30371300

years of experience

development projects

new product approvals around the world

Ora stands ready with over 100 ophthalmic profes sionals, three decades

of regulatory experience, the world’s largest network of ophthalmic clinical

sites, early stage development captial to help you turn your most promising

ideas into profitable products.

It all adds up to

The world’s leading ophthalmic product development firm

300 Brickstone Square | Andover, MA 01810 | (978) 494-4899

ois.oraclinical.com

Page 17: OIS@AAO October 16th, 2014

17

12:06 - 12:11 PM VESTRUM HEALTH

The mission of Vestrum Health is to capture the value of EHR data for the benefit of physicians, their patients and the healthcare industry. Vestrum Health aggregates EHR data from demographically and geographically diverse physician panels into special-ty-specific databases and products that have com-mercial value to healthcare and financial industries.

Tom BroganChairman of the Board

See bio on page 28

11:56 - 12:01 PM GOBIQUITY

Gobiquity mobile health brings specialty testing into primary care using mobile technology to capture clinically significant data. GoCheck Kids is the first product to be commercialized in their pipeline of digital diagnostics and screens young kids for risks of amblyopia, the preventable leading cause of vision loss in children.

Michael BrownellCEO

See bio on page 28

AG

END

A

12:01 - 12:06 PM DIGISIGHT

DigiSight Technologies, Inc. bridges the information gap between providers and mobile diagnostics. The company’s initial focus is to become a connectivity platform for ophthalmology. Ophthalmology is a specialty rapidly moving in-office diagnostics to mo-bile platforms. DigiSight Technologies facilitates this movement and enables the medical home concept to become reality. Doug Foster

CEO

See bio on page 36

DigiSightTM

12:11 - 12:16 PM APPVISIT

Improve patient care, save time and increase rev-enue. AppVisit facilitates e-visits between you and your patients. Offer asynchronous (no appointment necessary) virtual visits to your patients on smart-phones, tablets, and PC’s. AppVisit works for almost any patient condition and is also great for pre-visit intake forms, copayment collection, chronic condi-tion management and post-visit instructions. Harvey Fishman, MD, PhD

Co-Founder & Medical Director

See bio on page 34

Page 18: OIS@AAO October 16th, 2014

18

12:21 - 12:41 PM DIGITAL OPHTHALMOLOGY

1:10 - 1:35 PM PLENARY KEYNOTE

12:41 PM LUNCHEON COMMENCES

The Alcon/Google Partnership & Beyond

The Google/Alcon partnership is one of the more intriguing deals in ophthalmology in recent years. Hear the de-tails of how this joint-effort developed the next generation of contact lenses directly from those involved.

MODERATED BY:PANELISTS:

Gilbert H. Kliman, MDManaging DirectorInterWest Partners

See bio on page 42

Brian P. Otis, PhDFounder, Smart Contact Lens Project

Google XSee bio on page 48

Laurent AttiasHead, Global Commercial Strategy

AlconSee bio on page 26

Accelerating Innovation in Ophthalmology

For over 70 years, Alcon has built its leadership position in eye care through continuous innovation. Leveraging a strong innovation pipeline, coupled with acquisitions and licensing deals, Alcon is capitalizing on new technologies that will further expand one of the healthcare industry’s fastest-growing sectors.

Jeff George President & Global Head

AlconSee bio on page 38

AG

END

A 12:16 - 12:21 PM ASSORT

ASSORT ® is an ophthalmic software manufac-turer based in Melbourne, Australia and founded by ophthalmologist Dr Noel Alpins in 1992. The ASSORT® suite of products, which are designed for use in planning and analysing cataract and refrac-tive surgery, have extensive international patent and trademark protection.

Noel Alpins, MD, FACSCEO

See bio on page 26

Hosted By:

Page 19: OIS@AAO October 16th, 2014

781.768.3400 | [email protected] | www.avedro.comAvedro’s cross-linking systems and family of riboflavin products are not for sale in the US. MA-00396A

Advanced Corneal Cross-Linking: Topography Guided Refractive CXLAn Evening Event at AAO

Visit www.avedro.com/AAO2014 to register, or scan QR Code now

Join Avedro for an evening event at AAO featuring global thought leaders

speaking on advanced topics in corneal cross-linking.

Hyatt Regency Chicago Grand CD North 151 E. Wacker Drive Chicago, IL 60601

~cocktail reception to begin at 6:00 pm~

Saturday, October 18th

6:00 pm - 8:00 pm

Visit Booth #2175 for device demos!AAO | October 18-21 | Chicago

Page 20: OIS@AAO October 16th, 2014

20

1:35 - 2:00 PM OIS INNOVATOR AWARD PRESENTATION

2:00 PM LUNCHEON CONCLUDES

OIS continues to recognize trailblazers who have made exceptional contributions to ophthalmic innovation and entrepreneurship. Since the first award was presented in 2009, OIS has honored nine individuals who have achieved outstanding success in advancing ophthalmic innovation. The 2014 OIS Innovator Award goes to AGTC.

William W. Hauswirth, PhDCo-Founder

See bio on page 38

Nicholas Muzyczka, PhDCo-Founder

See bio on page 46

Susan WasherPresident & CEO

See bio on page 54

2:00 - 2:07 PM OPHTHALMIC INNOVATION 2014

2:07 - 2:15 PM OPHTHALMIC INNOVATION 2014

“A View From The AAO”

The aging global population continues to amp up demand for devices and drugs capable of treating the more vexing ophthalmic conditions. As a kickoff to its annual meeting, the CEO of the nation’s premier ophthalmology group will detail how industry is rising to supply physicians and patients with the necessary tools.

“A View From The NEI”

The surest supply of new drugs and devices will come through research funded with both public and private dollars. Hear how the NEI at the NIH will continue to nurse and nurture some of ophthalmology’s most innovative ideas.

David W. Parke, MD CEO

American Academyof Ophthalmology

See bio on page 50

Matthew J. McMahon, PhD Director, Office of Translational Research

National Eye InstituteNational Institutes of Health

See bio on page 46

AG

END

A

Page 21: OIS@AAO October 16th, 2014

Expanding Vision Innovations

acufocus.com

AcuFocus, Inc.

Visit us at AAO Suite #4648

MKU-102 Rev B

R E T I N A L D I S E A S E I S O U R F O C U S

To learn more, visit www.alimerasciences.com

Visit us at the AAOBooth 2834

Page 22: OIS@AAO October 16th, 2014

22

2:15 - 2:20 PM HOUSTON, WE HAVE A PROBLEM

Visual Disorders In Space And How Ophthalmology Can Help

Dorit Donoviel, PhD, Deputy Chief Scientist & Industry Forum Lead of the National Space Biomedical research Institute, will announce the creation of a new partnership between her agency and the ophthalmic industry, which plans to find ways to prevent and treat many of the eye issues associated with space travel.

Dorit B. Donoviel, PhD Deputy Chief Scientist& Industry Forum Lead

National Space BiomedicalResearch Institute

See bio on page 34

2:20 - 2:50 PM FDA Q&A

2:50 - 3:20 PM SECOND ACTS - REINVENTING YOUR COMPANY

3:20 - 3:50 PM AFTERNOON REFRESHMENT & NETWORKING BREAK

Industry’s hot and cold relationship with the FDA appears to be undergoing a warming trend as executives and entrepreneurs speak of the agency as a partner, rather than an adversary. In this discussion, senior FDA officials will share how ophthalmology companies can continue working well with the regulatory body.

The best ideas sometimes aren’t the ones that arrive early. A panel of experienced executives and investors will share how they have successfully turned obstacles into guideposts and transformed previously struggling compa-nies into major successes.

MODERATED BY:

MODERATED BY:

PANELISTS:

PANELISTS:

Stuart AbelsonPresident & CEO

OraSee bio on page 26

Ron Kurtz, MDFounderIntralase

See bio on page 42

William J. Link, PhDManaging DirectorVersant Ventures

See bio on page 42

Wiley A. Chambers, MDSupervisory Medical Officer, Division of Transplant & Ophthalmology Products

FDA

See bio on page 32

Mark ForchetteFormer CEOOptiMedica

See bio on page 34

Thomas G. FrinziPresident & CEO

WaveTec Vision SystemsSee bio on page 36

Malvina B. Eydelman, MDDirector, Division of Ophthalmic

Device EvaluationFDA

See bio on page 34

Vicente Anido Jr., PhDCEO

Aerie PharmaceuticalsSee bio on page 26

Emmett T. Cunningham Jr. MD, PhD, MPH

PartnerClarus Ventures

See bio on page 32

AG

END

A

Page 23: OIS@AAO October 16th, 2014

a proud supporter of OIS

Alcon is the global leader in eye care because we arepassionate about helping people see better. We are

dedicated to enhancing lives by enhancing sight,one of our most precious senses. We provide patientsinnovative products with the goal to deliver the best

patient outcomes. With our three businesses – surgical,pharmaceutical and vision care – we off er the widest

spectrum of industry-leading products that address thefull life cycle of eye care needs. We are proud of being a

trusted partner to professionals across the globe.

Enhancing Sight. Enhancing Lives.LEADING THE WAY IN EYE CARE

Page 24: OIS@AAO October 16th, 2014

24

3:50 - 4:00 PM PRIVATE FUNDING TRENDS PRESENTATION

4:00 - 4:10 PM THE OPTHALMOLOGY MARKET

Ophthalmology remains a popular target for private investors. Jon Norris, Managing Director of the Healthcare Practice at Silicon Valley Bank, will highlight recent financing trends.

Jonathan Norris Managing Director

SVBSee bio on page 48

4:10 - 4:40 PM IPOS IN OPHTHALMOLOGY - THE CLASS OF 2014 AND BEYOND

The IPO tide that swept through life sciences has enabled many eye care companies to set course for the public markets, providing new capital for companies and potential exiting opportunities for investors. Hear about what life is like on the public market and how other companies may follow the same path.

MODERATED BY:PANELISTS:

David R. Guyer, MDCEO

OphthotechSee bio on page 38

Amarpreet Sawhney, PhDPresident & CEO

Ocular TherapeutixSee bio on page 52

Thomas W. Chalberg, PhDFounder & CEO

Avalanche BiotechnologiesSee bio on page 30

Vicente Anido Jr., PhDCEO

Aerie PharmaceuticalsSee bio on page 26

Michael GaitoManaging Director, Head of West Coast Life Sciences

J.P. MorganSee bio on page 36

Susan WasherPesident & CEO

AGTCSee bio on page 54

Brian JohnsonPartner

WilmerHaleSee bio on page 40

Jeffrey Hoffman Managing Director

& Head of West Coast HealthcareInvestment Banking

J.P. MorganSee bio on page 40

A View Of The Public Sector & Exit Trends

Ophthalmology IPOs are on the rise. Jeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking at J.P. Morgan, shares how investors are viewing the sector.

AG

END

A

Page 25: OIS@AAO October 16th, 2014

25

4:40 - 5:10 PM INDUSTRY CONSOLIDATION

5:10 - 6:30 PM COCKTAIL RECEPTION

5:10 PM WRAP-UP & CLOSING COMMENTS

The Good, The Bad And The Unknown

The consolidation of ophthalmology leaders is impacting innovation at all levels. Hear from the sector’s leaders about what the future might bring.

MODERATED BY:PANELISTS:

Ashley McEvoyCompany Group Chairman

Johnson & Johnson Vision CareSee bio on page 44

William J. Link, PhDManaging DirectorVersant Ventures

See bio on page 42

James MazzoChairman & CEO

AcuFocusSee bio on page 44

David E.I. PyottCEO

AllerganSee bio on page 50

Murthy V. Simhambhatla, PhDPresident

Abbott Medical OpticsSee bio on page 52

Jeff GeorgePresident & Global Head

AlconSee bio on page 38

AG

END

A

Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and

marketing innovative specialty medicines to meet significant unmet patient needs. We provide treatments in Neuroscience,

Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions

treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

For more information regarding Shire, go to:

www.shire.com

Hosted By:

Page 26: OIS@AAO October 16th, 2014

26

Noel Alpins, MD, FACS | CEO - Assort

Dr Noel Alpins has been specialising in cataract and refractive surgery since founding NewVision Clinics in Melbourne in 1996. He speaks widely on these topics at national and international meetings. He has developed new techniques for treating and analysing astigmatism known as the Alpins Method which are journal published and described on Wikipedia and has developed the ASSORT array of surgical management computer programs for vector planning and analysis of treatment. Noel is on the editorial board of several ophthalmic information magazines and peer reviewed journals. Noel is being presented with the ISRS/AAO lifetime achievement award at the coming ISRA/AAO meeting this week.

Vicente Anido Jr., PhD | CEO - Aerie Pharmaceuticals

Dr. Anido was named Chief Executive Officer of Aerie Pharmaceuticals in July 2013 and was previously announced as Chairman of Aerie’s Board of Directors. He served as President and Chief Executive Officer of ISTA Pharmaceuticals from 2001 to 2012. Prior, he was general partner of Windamere Venture Partners, served as President and CEO of CombiChem, Inc. and President of Americas Region of Allergan. Dr. Anido serves on the Board of Directors of Depomed Inc. He received an M.S. in Pharmacy Administration from West Virginia University and Ph.D. in Pharmacy Administration from the University of Missouri-Kansas City.

Laurent Attias | Head, Global Commercial Strategy - Alcon

Mr. Attias has operational responsibility for commercial strategy across the Surgical, Pharmaceutical and Vision Care franchises. Before assuming his current role, Mr. Attias was President, Europe, Middle East and Africa (EURMEA). During his 18 years at Alcon, he progressed through the Sales and Marketing organizations by defining key strategic directions for the Surgical and Pharmaceutical franchises. Starting in 2002, Mr. Attias was VP, Refractive Sales and Marketing where he helped define Alcon participation in the Laser Refractive market. Prior to his move to Europe, he relocated to Toronto, Canada, where his operational contributions continued as VP/General Manager of Alcon Canada.

SP

EAKE

R BI

OS Stuart Abelson | President & CEO - Ora

Stuart Abelson is President & CEO of Ora, Inc., the global leader in ophthalmic research and product development. He has been a Director since 1995 and served as the Company’s Chairman from 1997 until his appointment as President in 2007. Mr. Abelson also serves as a Trustee at the Massachusetts Eye and Ear Infirmary, was a founder of Aciex Therapeutics and Entopica Therapeutics, and is a board member at Eye Therapies, LLC. Prior to joining Ora in an operating capacity, Mr. Abelson served in various management positions at Amphenol Corporation.

Page 27: OIS@AAO October 16th, 2014

NEW

Using the new ORA System® with VerifEye®+, it’s never been easier to set yourself up for better cataract outcomes. That’s because ORA’s new dynamic reticle makes it simple to line up placement for toric IOLs and LRIs, while streaming refractive information allows you to refine your IOL power selection and determine the magnitude and axis of astigmatism with ease.

Win big using the enhanced ORA System with VerifEye+. Visit WaveTec Vision® Booth 538 at AAO to learn more. www.getorasystem.com

IEC CLASS 1 LASER PRODUCT ORA System 2000 is marketed as the ORA System. The Intended use of the ORA 2000 System (ORA System or Optiwave Refractive Analysis) is to provide guidance to surgeons during cataract surgery. ©2014 WaveTec Vision. All rights reserved. WaveTec, WaveTec Vision, the WaveTec Vision logo, Optiwave, ORA System, the ORA System logo, and VerifEye are registered trademarks of WaveTec Vision. Data on file at WaveTec Vision. Individual results may vary. 80073 Rev D 08/14

GIMMEPower. Placement. Precision.

Allegro Ophthalmics has one goal: to quickly, safely and cost-e�ectively bring to market new and improved treatment options for the leading causes of blindness.

Allegro’s novel Integrin Peptide Therapy treats vitreo-retinal diseases by targeting the integrin receptors involved in constructing new and aberrant blood vessels. By utilizing both anti-angiogenesis and vitreolysis, Allegro’s lead molecule, Luminate®, stops and reverses in�ammation, vascular leakage, and neovascularization to restore vision.

Presently in Phase 2 studies, Luminate® has been shown to signi�cantly reduce the current burden of intravitreal injections and to be a viable option for patients with wet age-related macular degeneration and diabetic macular edema.

To learn more, visit www.allegroeye.com.

Integrin  Peptide  Therapy  for  the  Treatment  of  Vitreo-­Retinal  Diseases

Page 28: OIS@AAO October 16th, 2014

28

Shelley Boyd, MD, FRCSC | President & CSO - Translatum Medicus

Shelley Boyd, MD, FRCSC, is an Ophthalmologist specializing in diseases of the retina. She trained at the University of Toronto, with fellowships at Moorfields Eye Hospital, UK and the Scripps Research Institute, California. She is director of the Ocular Phenotyping Facility of the Toronto Centre for Phenogenomics, and the Walter Retinal Regeneration laboratory. She is Assistant Professor of Ophthalmology & Vision Sciences, with cross-appointment to Biomedical Engineering, McMaster University. Shelley was formerly Head of the Ocular Angiogenesis Research Program, worldwide, with Novartis (Switzerland), overseeing pre-clinical and translational aspects of the Ranibizumab program.

Tom Brogan | Chairman of the Board - Vestrum Health

Tom Brogan developed the market for health claims data over 20 years ago through his company, Brogan, Inc. An economist by training, Tom’s unique data initiatives ultimately altered both the market research landscape and sales force incentive programs. Tom grew Brogan, Inc into a 160-person health economic and heath data research company that was sold to IMS Health in 2010, after which Tom was appointed VP Global Oncology at IMS Health. In 2014, Tom joined Vestrum Health to lead the development of Vestrum’s unparalleled clinical database and analytics platform that creates value for physicians, patients, and the healthcare industry.

Michael Brownell | CEO - Gobiquity

Michael Brownell joined Gobiquity as CEO in 2012, with prior experience in a variety of leadership roles in ophthalmology and other industries. Gobiquity closed Series A financing with Interwest in July 2013. Michael was part of the initial management team at IntraLase, and at the time of acquisition by AMO he was VP of Product Development. While at AMO he had expanding responsibilities across multiple technology groups. Michael has an MS in physics and has held key roles at multiple start-ups, including Chief Technology Officer at Powerlase in the UK and VP of Product Development at GigaTera in Zurich.

SP

EAKE

R BI

OS Richard M. Awdeh, MD | Founder & CEO - CheckedUp

Dr. Awdeh is a surgeon at the Bascom Palmer Eye Institute, the US News & World Report # 1 Ranked Eye Hospital in the US for the past 10 years. He received his BBA in Finance from Emory University, where he was Valedictorian, worked at Goldman Sachs, and earned his MD from Yale University. Dr. Awdeh completed his training at the Memorial Sloan Kettering Cancer Center in NYC and at Duke University. Dr. Awdeh is the founder of CheckedUp, a mobile healthcare application focused on strengthening doctor-patient communications. He is also the Founder of Cirle, a medical technology incubator.

Page 29: OIS@AAO October 16th, 2014

Amakem’s lead product, AMA0076, is anovel highly potent locally-acting Rho Kinase(ROCK) inhibitor that has been designed totreat glaucoma by reducing intraocularpressure (IOP) while minimizing side effects.

In initial clinical trials, AMA0076demonstrated IOP reduction withoutsignificant hyperemia: the first ROCKinhibitor to achieve this goal in the clinic.

www.amakem.com

Amakem’s goal is totarget eye diseases withinnovative therapiesthat are locally-activeand therefore havefewer side effects...therapy for

ophthalmologyThink targeted...

Amakem corporate ad 7.5x4.62_awk_Layout 1 26/08/2014 08:37 Page 1

Page 30: OIS@AAO October 16th, 2014

30

Jeroen Cammeraat | CEO - i-Optics

Jeroen Cammeraat is CEO of i-Optics and investor in the company since 2010. A serial entrepreneur and senior executive with 20+ years of global experience in the medical technology and life sciences market. A former VP of Philips Electronics, where he joined the healthcare division in 1992. After 12 years with Philips he launched the European Discus Dental venture, a rapidly growing cosmetic dental company which was acquired by Philips in 2010. In 2010 Jeroen joined the global radiation therapy company Nucletron as COO where he led the successful management buy-out in 2007. Jeroen holds an MSc degree and an INSEAD MBA.

Ronen Castro | CEO - IOPtima

Ronen Castro is a seasoned medical device professional with 19 years of vast experience in the medical device industry. For the last 3 years prior to joining IOPtima, he was the CEO of Allium Medical Solutions (TASE:ALMD), a manufacturer of various MIS products. Previously, he served as the CEO of C-Boot, a manufacturer of advanced compression therapy products. For years he served in international marketing & sales and business development positions in few other Israeli medical device companies. He is also the founder of DCS Medical and EZ-Tube. Ronen Castro holds an MBA degree from Ben-Gurion University.

Thomas W. Chalberg, PhD | Founder & CEO - Avalanche Biotechnologies

Dr. Chalberg is a co-founder of Avalanche and has been a member of the board since July 2006. He has also served as President and CEO since October 2010. Prior to Avalanche, Dr. Chalberg worked at Genentech, where he held a number of roles in ophthalmology and oncology. From September 2001 to December 2005, Dr. Chalberg was a Howard Hughes Medical Institute Fellow at Stanford University, where his research focused on retinal diseases and new technologies for gene therapy. Dr. Chalberg is a member of the Board of Visionary Scientists for Hope for Vision, a nonprofit charity supporting vision research.

SP

EAKE

R BI

OS Robert Butchofsky | Founder & CEO - Mati Therapeutics

Bob is the Founder and CEO of Mati Therapeutics Inc. He was previously CEO of QLT from 2005-2012. During that time, he modified the company’s strategy and focused the company in ophthalmology acquiring innovative new technology including the punctal plug drug delivery technology from ForSight Labs. He joined QLT in 1998 and was responsible for QLT’s marketing of Visudyne®. He was employed at Allergan from 1990-1998 and now serves as Chairman of the Board of both Superna Life Sciences Inc. and of CDRD Ventures. He has a BA degree in Biology from the University of Texas and an MBA from Pepperdine University.

Page 31: OIS@AAO October 16th, 2014

Visit www.tearscience.com for complete product and safety information.

OPTIMIZE DRY EYE PATIENT CAREENHANCE YOUR EYE CARE PRACTICEIMPROVE LIPID SECRETIONS, INCREASE COMFORT, SATISFY PATIENTS

LIPIFLOW®

LIPIVIEW®

Surgical Management Systems

Visit our OIS booth

www.assort.comen.wikipedia.org/Alpins method

USA: +1 (800) 345 1632International: +61.3 9584 6966 [email protected]

• Our aim is to guide ophthalmologists to improve surgical techniques and outcomes using unique analyses

• Our systems provide complete confidentiality of reports

• The ASSORT systems can be networked within the clinic or for use by multiple clinic sites

Development of strategic relationships for international marketing and distribution

The development team seeks to establish partnerships with equity potential in ASSORT®

Products include extensive international patent and trademark protection

HINDSIGHT • INSIGHT • FORESIGHT

Page 32: OIS@AAO October 16th, 2014

32

Barry Cheskin | President & CEO - PowerVision

Barry Cheskin is Co-Founder, President & CEO of PowerVision. Mr. Cheskin has 20 years of general management experience in the medical device business. Prior to PowerVision, he was President & CEO of medical device company, NanoGram Devices, which he sold to his largest competitor. Prior to that, he was President & CEO of minimally invasive cancer device company RITA Medical Systems, which he took public in 2000. Prior to that, he was Division President at medical device company, Datascope. He holds a B.S. and M.S. in Mechanical Engineering from MIT and Stanford, respectively, and an MBA from Columbia Business School.

Emmett T. Cunningham Jr., MD, PhD, MPH | Partner - Clarus Ventures

Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals. He helped build and lead the team that developed and commercialized Macugen. Prior to Eyetech, Dr. Cunningham was at Pfizer. His responsibilities included the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 300 publications. Dr. Cunningham is the founder and Chairman of the Ophthalmology Innovation Summit (OIS).

Robert Dempsey | Vice President & Business Unit Head - Shire Ophthalmics

With more than 23 years of leadership experience the eye care space, Robert Dempsey joined Shire in February 2014 as Vice President and Head of Ophthalmology. He joined Shire from Bausch + Lomb as Executive Director, Pharmaceutical Medical Science North America. In that role, Robert served as a member of the Research & Development Leadership team, engaged in developing and supporting the overall medical strategy for commercially available products and pipeline assets. He worked closely to foster and enhance strategic relationships with Ophthalmic and Optometric thought leaders and support key medical affairs initiatives.

SP

EAKE

R BI

OS Wiley A. Chambers, MD | Supervisory Medical Officer, Division of Transplant &

Ophthalmology Products - FDA

Wiley A. Chambers, MD, is the Deputy Director of the Division of Transplant and Ophthalmology Products in the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA). He is currently a Clinical Professor of Ophthalmology and Adjunct Assistant Professor of Computer Medicine at The George Washington University. He joined the FDA in 1987, as a primary reviewer for ophthalmic drug products and, in 1990, became a Supervisory Medical Officer, responsible for the clinical review of ophthalmologic drug products and ophthalmic therapeutic biologic products submitted to the FDA for study and potential approval.

Page 33: OIS@AAO October 16th, 2014

 

 

 

WWW.SVLSA.COM

SV Life Sciences Advisers, LLC

SV Life Sciences is a global leader in international life sciences investing. SVLS affiliated funds have been investing in life sciences companies since the early 1980s. The SVLS team manages five venture capital funds with approximately $2 billion of capital commitments. SVLS employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services.

www.svlsa.com

One Boston Place Suite 3900

Boston, MA 02108 T: 617-367-8100 F: 617-367-1590

1700 Owens St, 1st Floor San Francisco, CA

94158 T: 650-571-8200 F: 650-571-8201

71 Kingsway London, WC2B 6ST

United Kingdom T: 44-207-421-7070 F: 44-207-421-7077

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have

approximately 11,700 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From

our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast

aesthetics, and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and customers who rely on our products and the

employees and communities in which we live and work.

For more information regarding Allergan, go to:

www.allergan.com

Page 34: OIS@AAO October 16th, 2014

34

Malvina B. Eydelman, MD | Director, Division of OphthalmicDevice Evaluation - FDA

Dr. Eydelman joined the FDA in 1995 and for the last 17 years, has served as the Director of FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices (DOED), and subsequently Director of the FDA’s Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices (DONED). Dr. Eydelman has been involved in all aspects of assuring the safety and effectiveness of ophthalmic medical devices. She also has been actively involved in standardization of ophthalmic devices as the U.S. Expert Delegate to the International Standards Organization and FDA’s Liaison to the American National Standards Institute‘s Committee for Ophthalmic Devices. award at the coming ISRA/AAO meeting this week.

Harvey Fishman, MD, PhD | Co-Founder & Medical Director - AppVisit

Dr. Harvey Fishman, M.D., Ph.D. is a Stanford-Trained Ophthalmologist, Diplomat of the American Board of Ophthalmology, and Fellow of the American Academy of Ophthalmology. He is the Founder and Former Director of the Stanford Ophthalmic Tissue Engineering Laboratory. Dr. Fishman has been published in numerous journals including Science, PNAS and The Archives of Ophthalmology. He holds ten Patents in the United States and is an invited speaker at International Ophthalmology Conferences. Dr. Fishman is also the Co-founder of AppMedicine, makers of AppVisit, a start-up specializing connecting patients with their providers on smartphones.

SPEA

KER

BIO

S Dorit B. Donnoviel, PhD | Deputy Chief Scientist & Industry Forum Lead - National Space Biomedical Research Institute

Dr. Donoviel oversees the diverse portfolio of science and technology research and development projects at NSBRI that address the challenges faced by humans in space. She leads the NSBRI Industry Forum and the SMARTCAP seed award program for commercialization of biomedical technologies co-developed for both space and Earth-based markets. Dr. Donoviel is Director of the Laboratory for Biomedical Innovations where she evaluates emerging medical products that have the potential to transform medical care in space and on Earth. Dr. Donoviel is also an Assistant Professor in the Department of Pharmacology and Center for Space Medicine at Baylor College of Medicine.

Mark Forchette | CEO - Delphinus Medical Technologies(Former CEO - OptiMedica)

Mr. Forchette is an accomplished medtech executive with demonstrated success transforming industries and driving breakthrough technologies to market. Prior to Delphinus, Forchette was president and CEO of OptiMedica Corporation, leading the company through the company’s acquisition by Abbott Laboratories in 2013. He began his career in medtech at Greishaber and Company, where he became VP of US sales and marketing, leading the company through its acquisition by Alcon. During his tenure at Alcon, he steered the tactical integration of Grieshaber, advanced to Vice President of vitreoretinal sales and global marketing, and led the retina portfolio through substantial market share gain.

Page 35: OIS@AAO October 16th, 2014

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye. w

ww

.ava

lanc

hebi

otec

h.co

m

Imagine a World Without Reading GlassesIntroducing the FluidVision® lens, the first “true” accommodating IOL (intraocular lens) that could change the way middle aged and elderly individuals see the future.

Developed by PowerVision, this proprietary technology is poised to help millions with cataracts or Presbyopia (age-related loss of near vision) avoid reading glasses and bifocals.

• These fluid-based lens implants have been shown in early clinical studies of patients undergoing cataract surgery to deliver excellent near, intermediate and distance visual acuity.

• Lenses are implanted using standard surgical techniques, the way the vast majority of IOLs are implanted today – in the capsular bag.

Contact us to find out how FluidVision can potentially restore the vision of youth.

www.powervisionlens.com

For more information contact Matt Frinzi: 650.620.9948 x211 | [email protected]

NOTE: The FluidVision® lens is an investigational device and it is not available for sale or use in the United States.

MKT06516 Rev A

Page 36: OIS@AAO October 16th, 2014

36

Doug Foster | CEO - DigiSight

Doug Foster is CEO of DigiSight Technologies, a leading connectivity platform for mobile health technologies. DigiSight integrates a broad array of mobile technologies into clinical practice and believes that interoperability is the cornerstone for more efficient delivery of healthcare. Mr. Foster has over 15 years experience identifying and developing technologies for the healthcare industry. Prior to DigiSight, Mr. Foster was a Managing Director at Longitude Capital, a venture capital firm dedicated to the life sciences. Prior to Longitude, he worked at Pequot Ventures which was the private equity division of Pequot Capital. He was a member of the healthcare team and focused on structured financings for medical device and biotechnology businesses.

John Freshley | CEO - ONL Therapeutics

John Freshley is the President and CEO of ONL Therapeutics having joined the company in July 2013. John is a serial entrepreneur with almost two decades of experience in leadership and founding roles of eight start-up companies with expertise in leadership team development, business strategy, business development and capital acquisition. Prior to ONL, John was Chief Business Officer of Compendia Bioscience through its acquisition by Life Technologies in 2012. John helped start the company in 2006 and served as its interim CEO. Previously, John had been President and CEO of Genetics Squared, a start-up focused on developing personalized oncology drugs.

Thomas G. Frinzi | President & CEO - WaveTec Vision Systems

Thomas G. Frinzi joined WaveTec as President and CEO in August 2010. Tom began his career at J&J and is a 30 year veteran of the ophthalmic and medical device industries. He served as VP of Global Commercial Operations at Bausch and Lomb Surgical. He held various executive roles at Refractec, including President, CEO and COO after an earlier role with Bausch and Lomb, where as Vice President of Sales, he managed numerous product launches with a focus on the growth and expansion of the ophthalmic market. His ophthalmic career also includes tenures at Chiron Vision Corporation, and Iolab Corporation.

SP

EAKE

R BI

OS

Michael Gaito | Managing Director, Head of West Coast Life Sciences - J.P. Morgan

Mr. Gaito is a Managing Director in J.P. Morgan’s Healthcare Investment Banking group responsible for the firm’s West Coast Life Sciences practice. He has been with J.P. Morgan and its predecessor firms for more than 18 years, beginning with Hambrecht & Quist’s Investment Banking group, focusing on the pharmaceutical industry. During this time, Mr. Gaito has advised clients on transactions representing more than $21 billion, with a focus on strategic advisory and financing assignments for biotechnology and pharmaceutical companies worldwide. Mr. Gaito received his AB degree from Princeton University and his MBA from Columbia University.

Page 37: OIS@AAO October 16th, 2014

PAN PTICA

Page 38: OIS@AAO October 16th, 2014

38

Jeff George | President & Global Head - Alcon

Jeff George was appointed Global Head of Alcon in May 2014. Mr. George has held leadership roles across four divisions of Novartis since January 2007. Prior to assuming his current role, Mr. George led Sandoz, the second-largest generic pharmaceutical company globally and the third-largest Novartis division. Prior to this, Mr. George was Head of Emerging Markets for the Middle East, Africa, Southeast Asia, and CIS for Novartis Pharma. Mr. George holds an MBA from Harvard University and a master’s degree from Johns Hopkins University’s School of Advanced International Studies. He also holds a bachelor’s degree from Carleton College.

Bernhard Günther | CEO - Novaliq GmbH

Bernhard Günther joined Novaliq as CEO in January 2007. He has more than 20 years of experience in ocular biopharmaceutics and medical devices. Prior to Novaliq, Mr. Günther served as CEO of Fluoron GmbH, pioneering the development of ophthalmic implants based on semifluorinated alkanes for the treatment of serious retinal diseases. At Fluoron, Günther was also responsible for the successful development and launch of the long-term endotamponade Densiron® 68 and the intraocular staining solution Brilliant Peel®. Mr. Günther served 10 years in leading senior management positions at Geuder AG. He also served as a Board Member of Fluoron GmbH.

David R. Guyer, MD | CEO - Ophthotech

David Guyer is CEO and Chairman of the Board of Directors of Ophthotech Corporation. He also serves on the boards of portfolio companies Allocure and PanOptica. Previously, Dr. Guyer, was a venture capitalist and Partner at SV Life Sciences. He has significant medical, drug development and commercial experience in ophthalmology. Following a career as Professor and Chairman of the Department of Ophthalmology at NYU School of Medicine, Dr. Guyer co-founded and served as CEO and Director at Eyetech Pharmaceuticals, Inc. Dr. Guyer received his Bachelor of Science degree from Yale College and his medical degree from Johns Hopkins Medical School.

SP

EAKE

R BI

OS

William W. Hauswirth, PhD | Co-Founder - AGTC

Dr. Hauswirth received his B.S. in Chemistry from Stanford University and his PhD in Physical Chemistry from Oregon State University. After an NIH Fellowship in the Biochemistry Department at Johns Hopkins University, he became an Assistant Professor. In 1976, he joined the faculty of Molecular Genetics and in 1985 the Ophthalmology faculty at the University of Florida. Dr. Hauswirth recently collaborated on the first successful rescue of a dominant genetic disease in animals and the first restoration of vision for a recessive retinal disease. His interests involve the delivery and testing of potentially therapeutic genes for Retinitis Pigmentos.

Page 39: OIS@AAO October 16th, 2014

WilmerHale is honored to support the 2014 Ophthalmology Summit @ AAO.

Shared Vision. Endless Possibilities.

wilmerhale.com © 2014 Wilmer Cutler Pickering Hale and Dorr llp

Page 40: OIS@AAO October 16th, 2014

40

Jeffrey Hoffman | Managing Director & Head of West Coast Healthcare Investment Banking - J.P. Morgan

Jeff Hoffman is a Managing Director and Head of West Coast Healthcare Investment Banking at J.P. Morgan. He has more than 20 years experience in the full range of investment banking activities including financial advisory services, mergers and acquisitions, equity and debt financings, and venture capital investments. Prior to joining J.P. Morgan, Mr. Hoffman was Head of Healthcare Investment Banking at Piper Jaffray, with execution focus on life sciences and medical technology clients. Mr. Hoffman received a BS in Psychology and an MBA from the University of North Carolina at Chapel Hill.

Henry Hsu, MD | Founder & CEO - Allysta Pharmaceuticals

Henry Hsu, MD is the founder and CEO of Allysta Pharmaceuticals. He has been engaged in ophthalmic drug development for over 10 years. He was most recently the co-founder and CEO of Altheos, Inc., where he led business development negotiations and raised over $32 million to develop a novel ROCK inhibitor for glaucoma. Prior to that, Dr. Hsu served as Chief Medical Officer (CMO) of Molecular Partners and has held various CMO and clinical research positions of increasing responsibility at CoMentis, Co-Therix, Intermune and Chiron. Dr. Hsu received his medical degree from the University of California, San Francisco.

Brian Johnson | Partner - WilmerHale

Brian Johnson has extensive experience representing public and private companies and financial institutions, including investment banking clients, in a wide variety of corporate finance and other strategic transactions. He also advises clients on a regular basis on general corporate and securities law and governance matters. Mr. Johnson represents clients in a range of industries and has a particular focus on life sciences and emerging growth companies. He is the co-chair of WilmerHale’s capital markets practice group.

SP

EAKE

R BI

OS

Vicken Karageozian, MD | Co-Founder & CTO - Allegro Ophthalmics

Dr. Karageozian is the CTO and co-founder of Allegro Ophthalmics and has 15+ years of experience in ophthalmic drug development at Allergan, ISTA Pharmaceuticals, and Vitreoretinal Technologies. Dr. Karageozian has extensive experience authoring and leading US and international human clinical trials, including novel trial designs and clinical endpoint strategies, clinical and regulatory leadership, and corporate strategy decision making in first-in-class clinical programs. He has been responsible for multiple Phase 2 and 3 studies involving hundreds of patients. Dr. Karageozian received his M.D. with Honors from Tufts University School of Medicine, and completed his ophthalmology residency at the University of California, Irvine.

Page 41: OIS@AAO October 16th, 2014

www.clarusventures.com

Clarus Ventures is a global investment firm

dedicated to life sciences.

We approach healthcare investing with

passion for novel ideas.

We strive to generate outstanding

returns for our investors.

We thrive on discovering innovative products to

improve people’s lives.

Emmett Cunningham, Jr., MD, PhD, MPH Nicholas Galakatos, PhD

Dennis Henner, PhD Finny Kuruvilla, MD, PhD

Jeffrey Leiden, MD, PhD Robert Liptak, MBA Michele Park, PhD

Scott Requadt, JD, MBA Edward Scolnick, MD Nicholas Simon, MBA

Michael Steinmetz, PhD Kurt Wheeler, MBA

William Young, MBA

Page 42: OIS@AAO October 16th, 2014

42

Gilbert H. Kliman, MD | Managing Director - InterWest Partners

Dr. Gil Kliman joined InterWest’s life sciences team in 1996. He invests in a broad array of life sciences opportunities with a special interest in ophthalmology and medical devices. He is a major investor in Epocrates (EPOC), Glaukos, IntraLase (ILSE), LenSx Lasers, Neuronetics, NeuroPace, On Demand Therapeutics, Restoration Robotics, and ReVision Optics. Prior to InterWest, Dr. Kliman was a healthcare investor at TA Associates and Norwest Venture Capital. As a practicing ophthalmologist he was the former west coast director of LCA Vision, and served on the clinical faculty at Tufts New England Eye Center and Massachusetts Eye and Ear Infirmary.

Ron Kurtz, MD | Founder - Intralase

Ron Kurtz is an ophthalmologist and entrepreneur, having co-founded IntraLase Corp and LenSx Lasers Inc. He has also served on the Ophthalmology faculty at the University of California, Irvine, and at the University of Michigan. Dr. Kurtz earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego.

Jesper J. Lange | President & Co-Founder - MC2 Biotek Group

Mr. Lange joined MC2 Biotek Group as co-founder in 2007 from his position as partner in a major Danish law firm. In addition to his experience in M&A and commercialization of IPR, Mr. Lange has strong entrepreneurial and business skills, including expertise in commercialization of drug development projects. Mr. Lange holds Masters of Law (LLM) degrees from Columbia University Law School in New York and the University of Aarhus, Law School, Denmark. Mr. Lange is dedicated to develop MC2 Biotek Group as a network based entity bringing together the strongest expertise and diverse science and business experience to create attractive biotech projects.

SP

EAKE

R BI

OS

William J. Link, PhD | Managing Director - Versant Ventures

Bill Link specializes in early-stage medical device investing at Versant. Prior to co-founding Versant Ventures, he was general partner at Brentwood Venture Capital. With extensive knowledge of medical devices, particularly in ophthalmology, his operating experience spans more than 23 years in general management. Bill has notable operational success in serving as founder, chairman and CEO of Chiron Vision, a subsidiary of Chiron Corporation specializing in ophthalmic surgical products, sold to Bausch and Lomb. Prior to Chiron Vision, Bill founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, sold to Allergan in 1986.

Page 43: OIS@AAO October 16th, 2014

Developing the Next Generation of Science-driven AMD Therapies

www.ophthotech.com

Fovista® Ophthotech’s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF drugs that represent the current standard of care for the treatment of wet AMD.

Zimura™ Ophthotech’s second product candidate, Zimura™, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy (a form of dry AMD) and, in combination with Fovista® and anti-VEGF therapy for wet AMD.

NASDAQ: OPHT

Page 44: OIS@AAO October 16th, 2014

44

John Maroney | CEO - ForSight VISION5

John Maroney is CEO of ForSight VISION5. John was a member of the Delphi Ventures for over ten years and continues his board relationship one of his portfolio companies. Prior to Delphi, John was President, CEO and Chairman of EndoTex Interventional Systems, which was acquired by Boston Scientific in 2007. John held a variety of senior management positions including President and General Manager at EP Technologies, VP of Operations at both Boston Scientific and Cardiovascular Imaging Systems (CVIS). While at CVIS, John was a member of the senior management team during the Company’s IPO and eventual acquisition by Boston Scientific.

James Mazzo | Chairman & CEO - AcuFocus

James (Jim) Mazzo is Chief Executive Officer (CEO) of AcuFocus, and Executive Chair of Neurotech. Mr. Mazzo’s focus is on patient needs, new technology advancements and investment opportunities in the healthcare field worldwide. Previously, Mr. Mazzo assumed the position of Senior Vice President, Abbott Laboratories and President, Abbott Medical Optics following the company’s February 2009 acquisition by Abbott. Prior to running the ophthalmic division for Abbott, he was Chairman and CEO of Advanced Medical Optics, Inc. after progressing through a 22-year career at Allergan.

Charlie McDermott | Interim President & CBO - Kala Pharmaceuticals

Mr. McDermott has 20 years of operating experience in the biotechnology and ophthalmology industries and currently serves as Kala’s Interim President and CBO. Previously he served as Vice President of Business Development, Eye Care and Drug Delivery at Allergan, and established partnerships that ranged from novel platforms (DARPins, PEMs, siRNA, etc.) to commercial products such as Acular™, Acuvail™, Latisse™ and Lastacaft™. Before joining Allergan, Mr. McDermott worked deCODE Genetics and Agouron Pharmaceuticals in business development, drug discovery, and regulatory affairs roles. Mr. McDermott holds degrees in business (MBA), Molecular Biology (MA), and Biochemistry (BA).

SPEA

KER

BIO

S

Ashley McEvoy | Company Group Chairman - Johnson & Johnson Vision Care

As company group chairman for Johnson & Johnson Vision Care, McEvoy leads one of the fastest-growing divisions of the global medical device segment. During her 17 years with J&J, McEvoy has worked with some of the company’s most powerful brands. McEvoy was previously worldwide President for Ethicon Products. Prior to joining Ethicon, she served as President of McNeil Consumer Healthcare. McEvoy joined Johnson & Johnson in 1996 as an assistant brand manager for Tylenol and Nicotrol. She became Vice President of marketing for McNeil’s consumer over-the-counter (OTC) business in 2003, and was promoted to General Manager of the OTC business in 2005 and President of McNeil Consumer Healthcare in 2006. Prior to Johnson & Johnson, McEvoy managed branding and advertising in Europe and the U.S. for Unilever and Procter & Gamble.

Page 45: OIS@AAO October 16th, 2014

www.forsightvision5.com

ForSight VISION5 is pleased to sponsor the Ophthalmology Innovation Summit.

We enjoy participating in this community of entrepreneurship and innovation, which is dedicated to helping patients see better.

www.ocutx.com AAO | Booth #2770

Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Our lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma. We are also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Our first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Page 46: OIS@AAO October 16th, 2014

46

Matthew J. McMahon, PhD | Director, Office of Translational Research, National Eye Institute - National Institutes of Health

Dr. Matthew McMahon completed his graduate studies in retinal structure, function, and visual perception at the University of California, San Diego and performed postdoctoral research in primate retinal physiology at the University of Washington. Previously serving as Senior Principal Scientist for Second Sight Medical Products and an AAAS Science and Technology Policy Fellow for the Senate Committee on Commerce, Science, and Transportation, he later served as professional staff on the House Science and Technology Committee. In his role at the National Eye Institute, Dr. McMahon facilitates translational research activities and participates in inter-agency initiatives.

David Muller, PhD | President & CEO - Avedro

Dr. Muller recognized the potential of using advanced methods to gently reshape the cornea and in 2007 founded Avedro, Inc., where he serves as the CEO. Under his direction, Avedro has pioneered numerous advances in the field of cross-linking, including accelerated cross-linking, pulsed illumination, Lasik Xtra, and photorefractive intrastromal cross-linking (PiXL). He was the Chairman of the Board and CEO of Summit Technology and he is the author of publications in the areas of photochemistry and excimer laser development. In addition he is the inventor of numerous patents in the medical device field.

Nicholas Muzyczka, PhD | Co-Founder - AGTC

Dr. Muzyczka received his PhD in biochemistry from Johns Hopkins University in 1974. He became the founding Director of the University of Florida Powell Gene Therapy Center and oversaw the development of many of the standard techniques currently used to manufacture AAV vectors. In 2001, Dr. Muzyczka and his colleagues founded AGTC. He was the founding CEO and Chairman of AGTC, and continues to serve as a scientific consultant. He is an inventor on over 20 issued or pending patents and served on the Board of Directors of the American Society for Gene Therapy and the NIH Recombinant Advisory Committee.

SP

EAKE

R BI

OS

Dan Myers | President & CEO - Alimera Sciences

Dan Myers is the co-founder, President and CEO of Alimera Sciences, Inc. Alimera’s ILUVIEN®, is an intravitreal implant for the treatment of diabetic macular edema. Under Dan’s leadership, Alimera successfully completed an IPO in 2010 and ILUVIEN has now been approved in 11 countries including most recently, FDA approval last month. Dan has 30 years of sales, marketing and general management experience in the ophthalmic pharmaceutical industry through tenures at Novartis Ophthalmics, Allergan and Johnson & Johnson. Dan has served on numerous ophthalmic charitable boards and currently holds a seat on the Board of the Georgia BIO organization.

Page 47: OIS@AAO October 16th, 2014

www.graybug.com

Extended Release Intravitreal Therapeutics

Through Micro Particle Drug Delivery

Page 48: OIS@AAO October 16th, 2014

48

Jonathan Norris | Managing Director - SVB

Jon Norris is a Managing Director with SVB Capital’s Venture Capital Relationship Management team, specializing in life sciences. Norris oversees strategic relationships with select life science venture capital firms on the West Coast, sourcing and advising on direct equity co-investment, limited partnership, and Portfolio Company banking and lending opportunities. In addition, he helps life science companies with equity fundraising strategy. Norris has more than eleven years of banking experience working with life science companies and venture capital firms. Norris earned a bachelor’s degree in business administration from the University of California, Riverside and a jurist doctorate from Santa Clara University.

Franz Obermayr, PhD | Co-Founder & CEO - Panoptes

Dr. Franz Obermayr is Co-founder and serves as Chief Executive Officer of Panoptes. Before that he was Head of Clinical Development at Nabriva, where he led the clinical efforts to show clinical POC in a phase 2b study leading to the successful Biotech-deal with Forest Laboratories. Before that he held several positions at GPC-Biotech where he led development programs in Germany and US and played a key role in commercialization these programs with pharmaceutical companies. Prior to GPC-Biotech he did his postdoctoral studies at the Max-Planck Institute for Immunobiology.

Michael O’Rourke | President & CEO - GrayBug

Michael has 20 years of global ophthalmic leadership experience across pharmaceuticals, drug delivery and medical devices. He was appointed President & CEO of GrayBug in 2013, a new ocular pharmaceutical and drug delivery company developing new therapeutics in w-AMD and glaucoma. Previous experience includes General Manager for Bausch + Lomb Pharmaceuticals, Chiron Vision Europe, Alza, Pfizer and 3M Pharma. Michael has managed 26 brands, led 13 product launches, and has been a team member in 19 device/drug approvals. He is Foundation Board Chairman for Lions Eye Institute, the world’s largest Eye Bank with a unique Ocular Research Center.

Brian P. Otis, PhD | Founder, Smart Contact Lens Project - Google X

Dr. Brian Otis is the founder of Google [x]’s smart contact lens project. He received a B.S. in electrical engineering from the University of Washington, Seattle, and a M.S. and Ph.D. degree in electrical engineering from the University of California, Berkeley. He joined the faculty of the University of Washington in 2005 where he runs a chip design research lab that designs tiny, low power chips.

Max G. Ostermeier, MBA | Co-Founder & General Manager -Implandata Ophthalmic Products GmbH

Max has extensive experience in the commercial development of technologically advanced products and in building operational capabilities for aggressively growing companies. As serial entrepreneur he was founder and CEO of several medical device start-up companies in Germany and the US and instrumental to proceed these companies to a successful exit. For close to 15 years now, Max is involved in the development of ophthalmic surgical products, working with leading institutes and researches in order to address currently unmet medical needs in eye care.

SP

EAKE

R BI

OS

Page 49: OIS@AAO October 16th, 2014

...Proud to Be a Part of the Innovative Spirit of OIS 2014

...Developing a First-In-Class Versatile Platform for Continuous Delivery of Proteins to the Posterior Segment

...Pioneering the Use of a Genetically Engineered Proprietary Cell Line to Produce Targeted Therapies

Page 50: OIS@AAO October 16th, 2014

50

David W. Parke, MD | CEO - American Academy of Ophthalmology

Dr. Parke is CEO for the American Academy of Ophthalmology. Prior to assuming this role, Dr. Parke served for 17 years as president and chief executive officer of the Dean McGee Eye Institute, and Edward L. Gaylord Professor and Chair of the Department of Ophthalmology in the University of Oklahoma College of Medicine. For 27 years he was a clinically active vitreoretinal surgeon, clinical investigator, and teacher. A graduate of Stanford University and an AOA graduate of the Baylor College of Medicine, Dr. Parke completed residency training at Baylor College of Medicine, serving as chief resident.

David E.I. Pyott | CEO - Allergan

David E.I. Pyott joined Allergan in 1998 and, during his tenure, has transformed Allergan from a small eye care business to a global specialty pharmaceutical and medical device company. Before joining Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of the Switzerland-based Novartis AG. Mr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh and a Master of Business Administration degree from the London Business School.

Jane Rady | Divisional Vice President, Business Development - Abbott Medical Optics

Jane E. Rady is divisional vice president, business development at Abbott Medical Optics (AMO). Prior to AMO’s acquisition by Abbott in 2009, Ms. Rady was a corporate officer of Advanced Medical Optics. Prior to joining AMO, Ms. Rady was CEO of Integrated Genomics, Inc. and was a consultant to Integrated Genomics and several other companies. From 1984 to 2000, she was employed by G.D. Searle & Co. in various capacities. Prior to that, she headed venture investing activities in Monsanto focusing on emerging technologies and businesses in biotechnology. Ms. Rady began her career in Chicago with Abbott Laboratories.

SP

EAKE

R BI

OS Quinton Oswald | President & CEO - Neurotech

Quinton Oswald is the CEO of Neurotech. Prior to joining Neurotech, he served as the CEO of SARcode Bioscience, a San Francisco-based biotech that developed lifitegrast, an investigational product for dry eye disease. Previously, he was Vice President & Business Unit Head for Genentech’s Tissue Growth and Repair Business. During his tenure at Genentech, Mr. Oswald directed the highly successful commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD. Prior to Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD.

Page 51: OIS@AAO October 16th, 2014

About Morgenthaler Ventures. As active investors, we have partnered with some of the world’s most visionary entrepreneurs. Morgenthaler Ventures is a premier venture capital firm with $3 billion under management. We have invested in more than 300 companies in the life science and information technology sectors. Representative life science companies include: Ardian, OncoMed, Transcend, Nexis Vision, Promedior, Elcelyx, Holaira, Kona Medical, Moximed, Ra Pharmaceuticals, SetPoint Medical, Scioderm, Second Genome, and incubators The Foundry and ForSight Labs.

www . m o r g e n t h a l e r . c o m

Page 52: OIS@AAO October 16th, 2014

52

Paul Rubin, MD | CMO - XOMA

Dr. Paul Rubin is XOMA’s SVP, Research and Development & Chief Medical Officer. He joined the company in 2011. Prior to XOMA, Dr. Rubin was CMO at Funxional Therapeutics Ltd. He was CEO of Resolvyx Pharmaceuticals, Inc. and President and CEO of Critical Therapeutics, Inc. Prior to that, Dr. Rubin served as SVP, Development, and later as EVP, Research & Development at Sepracor. Additionally, Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals and Abbott. Paul received a BA from Occidental College and his M.D. from Rush Medical College. He completed his training in internal medicine at the University of Wisconsin.

Amarpreet Sawhney, PhD | President & CEO - Ocular Therapeutix

Amarpreet Sawhney, PhD, is the President, CEO, and Chairman of the Board for Ocular Therapeutix. Dr. Sawhney was previously the founder and CEO of Confluent Surgical (acquired by Covidien), the Chairman of MarketRx (acquired by Cognizant), and technology founder of Focal, Inc. (acquired by Genzyme) and Access Closure Inc. (acquired by Cardinal Health). Dr. Sawhney’s innovations are the subject of over 120 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.

Murthy V. Simhambhatla, PhD | President - Abbott Medical Optics

Murthy Simhambhatla, Ph.D., is Senior Vice President, Abbott Medical Optics, heading up the company’s global vision care business. Dr. Simhambhatla was appointed to this position in January 2013. Previously, he served as General Manager of the Ibis Biosciences unit of Abbott Diagnostics. Dr. Simhambhatla joined Abbott in 2006 through its acquisition of Guidant Corporation, as Divisional Vice President and General Manager for Drug Eluting Stents. He also served as General Manager for commercial operations in Australia and New Zealand for Abbott Vascular. Before joining Guidant, Dr. Simhambhatla worked in research and development at Raychem Corporation in Menlo Park, CA.

SP

EAKE

R BI

OS Calvin W. Roberts, MD | Executive Vice President & CMO - Bausch + Lomb

Calvin W. Roberts, M.D. is Executive Vice President and the Chief Medical Officer at Bausch + Lomb. A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics and innovative treatment regimens. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals. Dr. Roberts is a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, and a member of the board of directors of Alimera Sciences.

Page 53: OIS@AAO October 16th, 2014

build winning technology and healthcare companies. We have a long-standing

including AGTC, Glaukos, Gobiquity, IntraLase (acquired by AMO), LenSx (acquired

turn their ideas into a thriving company.

www.interwest.com

GT

C

A

Compounded mitomycin degrades rapidly1.

So what you want and what you get could be a shot in the dark.

Mitosol® is reconstituted on the sterile field at the time of use.

So it’s right on the mark every time2.

Eliminate one more variable from your surgery.

Choose Mitosol®.

BLIND FAITHIsn’t What You Learned in Medical School

Mitosol® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use

2014 0007For brief prescribing information visit www.mobiustherapeutics.com.

INDICATIONMitosol® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.Dosage & AdministrationMitosol® is intended for topical application to the surgical site of glaucoma filtration surgery and must be reconstituted prior to application. Sponges provided within the Mitosol® Kit should be fully saturated with the entire reconstituted contents in a manner prescribed in the Instructions For Use. The sponge(s) should be applied to the treatment area for two minutes.Reconstituted Mitosol® should be used within one hour of reconstitution.

IMPORTANT SAFETY INFORMATIONContraindicationsMitosol® is contraindicated in patients that have demonstrated a hypersensitivity to mitomycin, and in women who are or may become pregnant during therapy.Warnings & PrecautionsCell Death, mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or scleral damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death. Hypotony. The use of mitomycin has been associated with an increased instance of post-operative hypotony.Cataract Development. Use in phakic patients has been correlated to higher instance of lenticular change and cataract formation.Adverse events and reactionsThe most frequent adverse reactions to Mitosol® occur locally and include hypotony, hypotony maculophathy, blebitis, endophthalmitis, vascular reactions, corneal reactions, and cataract.

1 Degradation of Mitomycin Under Various Storage Conditions; Kinast RM, Mansberger SL; Poster 83-111; AGS 20142 Data on file; Mobius Therapeutics, LLC and US Food and Drug Administration; NDA #22-572

Get More Information at www.mobiustherapeutics.com 1-877-EYE-MITO (1-877-393-6486)

Mitosol®: The Choice is Yours.

Compliance. Containment. Consistency. Cost.

Page 54: OIS@AAO October 16th, 2014

54

Russell Trenary | President & CEO - InnFocus

Russ Trenary is President & CEO for InnFocus, Inc., an early stage company pioneering a microsurgical solution for glaucoma. He has led, or been a named officer, for medical device companies, for over 20 years. His managerial experience includes specific interfacing in Marketing / Sales / Finance / R&D / Clinical / Regulatory / Manufacturing. He has turned unprofitable $100MM divisions at Allergan (NYSE:AGN) into highly profitable entities, and also significantly increased profitability in $500MM divisions at AMO (NYSE:EYE). He also has vast experience with large volume product launch and company acquisitions.

Susan Washer | President & CEO - AGTC

Sue Washer, President and CEO of AGTC, is an experienced entrepreneur with a strong scientific and operational background. She has a degree in biochemistry from Michigan State University and an MBA from the University of Florida. Sue has 10 years of management and research experience with Abbott and Lilly. At Abbott Ms. Washer led teams bringing new products and technologies from the lab bench into the marketplace. Ms. Washer has 16 years of senior management experience with entrepreneurial firms. At AGTC, Ms. Washer has successfully raised over $43M and led a collaboration with a top five Biotech.

Tim Willis | Co-Founder & CEO - TearScience

Mr. Willis has more than 35 years of medical device industry experience. Tim is an entrepreneur and inventor and has been responsible for the development and launch of 50+ products that today represent over a half billion dollars in annual sales. He has served as senior management, R&D, marketing, and corporate and business development at several leading healthcare corporations. Tim is a scientist and engineer who sits on the Board of TearScience, Life Branch Institute and Trinity Academy. He is a member of the ASCRS, ARVO, and Licensing Executive Society and a Fellow of the American Academy of Optometry.

SP

EAKE

R BI

OS Ed Timm | President & CEO - Mobius Therapeutics

Ed has more than 25 years experience in the surgical device/life science industry. He has initiated and/or grown sub-specialty franchises for multiple companies, to include American Hospital Supply Corporation, Applied Medical Resources, Storz Ophthalmics, and Given Imaging, Ltd.. Most notably, he was responsible for Commercial Development at Synergetics, Inc., taking the company from start up status to a M$40 public company, operating successfully in sixty countries and two surgical disciplines. Mr. Timm holds a B.A. degree in Philosophy from the University of Dayton and is the holder of seven issued US patents, with numerous patents pending.

Page 55: OIS@AAO October 16th, 2014

For information on all current opportunities, please visit our

website at www.agtc.com/careers.

Visionary science for life changing cures.

Imagine that the power to beat genetic disease is within us.AGTC is a clinical stage biotechnology company developing novel systems to deliver human therapeutics. Our team exceeds expectations every day, placing a high standard on integrity and open communication in all areas of our business enterprise.

We are always looking for technical and business professionals who are eager to have a significant impact on improving patient care. If you are highly self-motivated; comfortable working as part of a cross-functional team; enjoy interdisciplinary problem-solving; and want to work in an extremely dynamic and fast-paced environment, then you may be a great fit on our team.

AGTC is an equal-opportunity employer, offering competitive cash and stock-based compensation, excellent employee benefits and tremendous opportunity for personal and professional growth in an outstanding and intellectually-challenging work environment. Competitive compensation is offered commensurate with education and experience of the successful candidate, including salary, benefits, and company equity. AGTC is an EOE and maintains a drug free workplace.

11801 Research Drive, Suite D • Alachua, FL 32615

1Cassini 3°2Placido 13°

3Scheimpflug 30°i-Optics releases new Cassini Corneal Shape Analysis functionality to measure both anterior and posterior astigmatism, providing refractive-cataract and cornea surgeons with a Total Corneal Astigmatism (TCA) measurement.

Cassini TCA - Premium treatment starts with premium diagnosis!

Interested in improving your toric and LRI outcomes ?Measuring Posterior Astigmatism ?

TOTAL CORNEAL ASTIGMATISM

For more information: Call us at 888-660-6965. Contact us at [email protected] Or visit www.i-optics.com

Meet us at theOIS-AAO

BOOTH #1671

1 : A. John Kanellopoulos, MD. Clinical Professor Of Ophthalmology, New York University Medical School - Submitted. 2 : Karabatsas et al. BJO 2005. 3 : McAlinden et al. IOVS 2011

Page 56: OIS@AAO October 16th, 2014

BE A PART OF SHOUTMDShoutMD is the first “Procial,” professional and social, community designed exclusively

for board certified specialists to share new insights, discuss the latest research and

collaborate with peers to improve patient experiences and outcomes.

DOWNLOAD SHOUTMD TODAY Text the word Shout to 74121 to download the app or visit www.shoutmd.com.

I find myself logging on to ShoutMD on a daily basis. Unique

to this site is communication between surgical specialists

in multiple fields outside ophthalmology and the active participation of brilliant minds

in business, finance and practice management. ShoutMD is destined to be my favorite media site, and is already a

game changer in medical blogs. I recommend without reservation

active participation to all my colleagues who are eligible.

Richard Lindstrom, MDBoard Certified Ophthalmologist

ARE YOU AN INNOVATOR? IS YOUR VOICE BEING HEARD?

JOIN THE CONVERSATION

Page 57: OIS@AAO October 16th, 2014

©2013, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 All rights reserved 09/2013 RGN-0108

Kala Pharmaceuticals, Inc. isadvancing innovative nanoparticle- based treatments for ocular diseases by enhancing local drug delivery with its proprietary Mucus- Penetrating Particle (MPP) platform.

www.Kalarx.com

Innovative Nanotechnology Delivery

Page 58: OIS@AAO October 16th, 2014

www.InnFocusInc.com

The next small thing in glaucoma surgery.

Think Low.

INNF-12918 OIS at AAO 2014 Ad r3.indd 10/1/14

4c — 0

7.5” x 4.625” N/A

PAD™ Technology – releasing the full potential of API’s

www.mc2biotek.com

INTRODUCING PADciclo™

- BECAUSE TOLERABILITY MATTERSPreservative free, unit dose, once daily ciclosporin eye drop

Page 59: OIS@AAO October 16th, 2014

59

Abbott Medical Optics | Exclusive Sponsor

Abbott Medical Optics is focused on delivering life-improving vision technologies to people of all ages. The company offers a comprehensive portfolio of cataract, refractive and eye care products. AMO is headquartered in Santa Ana, California, employing approximately 4,000 worldwide.

www.abbottmedicaloptics.com

AcuFocus | Strategic Sponsor

AcuFocus is the leader of small aperture optics, focusing on technologies to improve near vision for presbyopic patients. AcuFocus is the exclusive global distributor of the AcuTarget HD™ diagnostic and surgical planning instrument providing practices objective data to support patient selection, proper centration for approved inlays and post-operative management.

www.acufocus.com

Aerie Pharmaceuticals | Major Sponsor

Aerie is a clinical-stage pharmaceutical company with a focus on glaucoma therapies. Aerie commenced two Phase 3 registration trials in the US for triple-action Rhopressa™ named “Rocket 1” and “Rocket 2, a third Phase 3 safety trial, named “Rocket 3,” in Canada and a Phase 2b clinical trial for quadruple-action Roclatan™.

www.aeriepharma.com

AGTC | Supporting Sponsor

AGTC uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC’s lead product candidates focus on orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.

www.agtc.com

Alcon | Major Sponsor

Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people see better. The three Alcon businesses - Surgical, Pharmaceutical and Vision Care - offer the widest spectrum of eye care products in the world. Alcon’s the second largest division of Novartis.

www.alcon.com

SPON

SOR PRO

FILES

Page 60: OIS@AAO October 16th, 2014

60

Alimera Sciences | Supporting Sponsor

Alimera Sciences is a pharmaceutical company focused on diseases affecting the retina. Its product, ILUVIEN® (fluocinolone acetonide intravitreal implant) has received marketing authorization for chronic diabetic macular edema considered insufficiently responsive to available therapies in Austria, Denmark, France, Italy, Norway, Portugal and Spain, and has been launched in Germany and the UK.

www.alimerasciences.com

Allegro Ophthalmics | Supporting Sponsor

Allegro quickly, safely and cost-effectively bring to market new and improved treatment options for the leading causes of blindness. In only four years, Allegro has progressed Luminate® from drug discovery, to establishing safety and initial efficacy in both animals and human patients, to phase 2 clinical trials in DME and vitreomacular traction.

www.allegroeye.com

Allergan | Strategic Sponsor

Allergan is committed to uncovering the best of science by developing and delivering innovative and meaningful treatments to help people reach their life’s potential. Allergan has a presence in more than 100 countries, a rich and ever-evolving portfolio, and state-of-the-art resources in R&D, manufacturing and safety surveillance.

www.allergan.com

ALPHAEON | Major Sponsor

ALPHAEON is a lifestyle healthcare company committed to partnering with board-certified physicians to bring to market and develop highly innovative technologies and services that promote patient wellness, beauty and performance. ALPHAEON fosters deep relationships with leading specialty physicians so patients receive the best in lifestyle healthcare.

www.alphaeon.com

Amakem Therapeutics | Supporting Sponsor

Amakem Therapeutics is a clinical-stage ophthalmology company developing innovative treatments for serious eye conditions. The Company’s goal is to create therapies based on its “Localized Drug Action” platform, minimizing systemic exposure and reducing side effects. Amakem’s lead product, AMA0076, is designed to treat glaucoma by reducing intraocular pressure while minimizing side effects.

www.amakem.com

SPO

NSO

R PR

OFI

LES

Page 61: OIS@AAO October 16th, 2014

61

Assort | Supporting Sponsor

ASSORT ® is an ophthalmic software manufacturer based in Melbourne, Australia and founded by ophthalmologist Dr Noel Alpins in 1992. The ASSORT® suite of products, which are designed for use in planning and analysing cataract and refractive surgery, have extensive international patent and trademark protection.

www.assort.com

Avalanche Biotechnologies | Strategic Sponsor

Avalanche, a clinical-stage biotechnology company, discovers and develops novel gene therapies to treat sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, Avalanche provides long-term benefits or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.

www.avalanchebiotech.com

Avedro | Premier Sponsor

Avedro is a privately held medical device and pharmaceutical company developing corneal cross-linking, a non-invasive treatment for refractive disorders and certain pathologies. Avedro sells in 62 countries and recently submitted an NDA to the FDA. Avedro is also developing, Photorefractive Intrastromal Cross-Linking (PiXL™), for post-cataract ametropia and refractive correction.

www.avedro.com

Bausch + Lomb | Strategic Sponsor

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including contact lenses and lens care products, pharmaceuticals, intraocular lenses and other eye surgery products.

www.bausch.com

Clarity Medical Systems | Strategic Sponsor

Clarity Medical Systems is a medical device company that develops, manufactures and markets integrated optical systems and services to enhance the clinician’s ability to diagnose, manage, and treat eye disorders. These patented devices combine innovative optical, electronic and information technologies, changing the very nature of the provision of eye healthcare.

www.claritymsi.com

SPON

SOR PRO

FILES

Page 62: OIS@AAO October 16th, 2014

62

Clarus Ventures | Founding Sponsor

Clarus Ventures is a global investment firm dedicated to life sciences. The deep domain expertise of the Clarus team allows us to employ a hands-on philosophy of providing value enhanced leadership and guidance in working with our management teams in both the biopharmaceutical and medical device arenas.

www.clarusventures.com

Eleven Biotherapeutics | Supporting Sponsor

Eleven Biotherapeutics is a clinical-stage biopharmaceutical company with a protein engineering platform, called AMP-Rx. Eleven’s approach uses insights into the structural biology of cytokines and their role in diseases of the eye. Eleven’s, EBI-005, is in clinical development as a topical treatment for dry eye disease and allergic conjunctivitis.

www.elevenbio.com

ForSight VISION5 | Supporting Sponsor

ForSight VISION5 is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy.

www.forsightvision5.com

Genentech | Premier Sponsor

Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

www.gene.com

GrayBug | Supporting Sponsor

GrayBug has developed a technology to reduce the frequency of treatment injections to every 4 to 6 months, reducing risks associated with repeated intraocular injections. In addition, GrayBug is applying its novel technology to a lead compound that blocks both key pathways of neovascularization in w-AMD, VEGF and PDGF.

www.graybug.com

SPO

NSO

R PR

OFI

LES

Page 63: OIS@AAO October 16th, 2014

63

iCo Therapeutics | Strategic Sponsor

iCo Therapeutics has exclusive rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies. With Phase 2 clinical history, iCo-008 is targeted for the treatment of vernal or atopic keratoconjunctivitis and wet age-related macular degeneration.

www.icotherapeutics.com

IDDI | Supporting Sponsor

IDDI’s mission is to optimize the clinical development of drugs, biologics and devices using innovative integrated eClinical technologies with expert methodology in biostatistics to optimize the design, conduct and data analysis of clinical trials.

www.iddi.com

InnFocus | Supporting Sponsor

InnFocus MicroShunt ™ addresses the largest glaucoma patient segment and has achieved mean post op IOP’s below 14 mm Hg, and 80% med reduction. IOP reduction at 3 months similar to 3 year. By 12/31/14, over 20 doctors will have treated over 150 patients, followed for up to 3 years.

www.infocusinc.com

InterWest Partners | Founding Sponsor

For over 30 years InterWest has partnered with entrepreneurs to build winning technology and healthcare companies. With over 200 years of combined operating and investing experience, the InterWest team believes providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving company.

www.interwest.com

i-Optics | Strategic Sponsor

i-Optics pioneers smart and superior eye diagnosis solutions that are affordable, fast and user-friendly for care providers worldwide. Their innovations include: Cassini – A first-of-its-kind Corneal Shape Analyzer, EasyScan – A breakthrough, zero-dilation retinal imaging system to diagnose retinal diseases, and EyePrevent –An effective and cost-efficient retinal disease screening service.

www.i-optics.com

SPON

SOR PRO

FILES

Page 64: OIS@AAO October 16th, 2014

64

Kala Pharmaceuticals | Supporting Sponsor

Kala Pharmaceuticals, Inc. is advancing innovative nanotechnology-based treatments for ocular diseases with significant unmet needs in both front and back of the eye. Kala leverages the company’s proprietary Mucus Penetrating Particle platform technology to develop topical ophthalmic formulations that enhance ocular tissue exposure by facilitating penetration through the mucus layer.

www.kalarx.com

MC2 Biotek Group | Supporting Sponsor

The privately held MC2 Biotek is using its unique and patented oil-in-water dispersion - PAD™ Technology - in the ophthalmic and dermatological fields. PAD™ Technology enables release of the full potential of API’s and is the basis for comfortable and patented topical drugs that will improve patient compliance and clinical benefits.

www.mc2biotek.com

Mobius Therapeutics | Supporting Sponsor

Mobius Therapeutics™ believes that retasking of molecules is more efficient than drug discovery. Standard of care indications creates NDA’s with less burdensome provisions. The resulting entity creates 6 products in multiple subspecialties. Revenues fund new solutions to existing problems for evolving products and procedures.

www.mobiustherapeutics.com

Morgenthaler Ventures | Founding Sponsor

Morgenthaler Ventures, a premier venture capital firm with $3 billion under management, invested in over 300 companies in life sciences and information technology - Ardian, OncoMed, Transcend, Nexis Vision, Promedior, Elcelyx, Holaira, Kona Medical, Moximed, Ra Pharmaceuticals, SetPoint Medical, Scioderm, Second Genome, and incubators The Foundry and ForSight Labs.

www.morgenthaler.com

Neurotech | Supporting Sponsor

Neurotech Pharmaceutical’s core technology, Encapsulated Cell Therapy (ECT), is a proprietary first-in-class drug delivery platform for the treatment of chronic eye diseases. The ECT implant enables continuous immune-privileged production and delivery of therapeutic proteins, derived from a customized cell line, for at least two years to the posterior segment.

www.neurotechusa.com

SPO

NSO

R PR

OFI

LES

Page 65: OIS@AAO October 16th, 2014

65

Novaliq GmbH | Supporting Sponsor

Novaliq GmbH, based in Heidelberg, is a drug delivery company that is developing a superior generation of innovative ocular formulations for poorly soluble drugs. The patented ocular formulations are based on semifluorinated alkanes (SFAs), which can be easily applied in the form of topical eye drops.

www.novaliq.de

Ocular Therapeutix | Supporting Sponsor

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The Company is currently evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved.

www.ocutx.com

ONL Therapeutics | Supporting Sponsor

ONL Therapeutics preserves vision through the protection of photoreceptors from retinal disease. ONL is developing ONL-101, a small injectable peptide that blocks photoreceptor apoptosis. Initial development targets retinal detachment with a neoadjuvant therapy at time of diagnosis and prior to surgery. Further development will protect photoreceptors until the disease is stabilized.

www.onltherapeutics.com

Ophthotech | Strategic Sponsor

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, with a focus on developing innovative therapies for age-related macular degeneration. Ophthotech’s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF drugs.

www.ophthotech.com

Ora | Exclusive Sponsor

Ora is the world’s leading independent, full-service ophthalmic research and product development firm. Over the past 30 years, Ora has helped their clients earn 37 FDA approvals. Ora supports a wide array of organizations to efficiently and successfully bring their new products from concept to market.

www.oraclinical.com

SPON

SOR PRO

FILES

Page 66: OIS@AAO October 16th, 2014

66

Pacific Eye & Laser Institute | Supporting Sponsor

PPacific Eye and Laser Institute (PELI) is committed to delivering high quality, comprehensive eye care in a caring environment. From prescription of eyeglasses to treatment of various eye diseases, PELI offers a wide range of services and procedures that answer all your eye care needs. The ophthalmologists, optometrists, nurses and staff at PELI work together to provide you with first-rate patient care that you go home satisfied for choosing PELI for your eye care needs.

www.pacificeye.com.ph

PanOptica | Supporting Sponsor

Co-Founders, Paul Chaney and Martin Wax, MD, are recognized leaders in the search, evaluation, licensing, development and commercialization of ophthalmic pharmaceuticals. PAN-90806 is a novel topically administered VEGF antagonist for the treatment of neovascular AMD. PanOptica’s currently enrolling patients in a dose-ranging phase 1/2 study, testing safety and biological response.

www.panopticapharma.com

PowerVision | Supporting Sponsor

PowerVision, Inc. has developed a proprietary fluid-controlled accommodating intraocular lens (IOL) technology designed to restore youthful vision to millions of middle aged or elderly individuals. The Company has proven in recent clinical trials that it can deliver clear near, intermediate and distance vision with its fully injectable accommodating device.

www.powervisionlens.com

Regeneron | Major Sponsor

Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical needs.

www.regeneron.com

Shire Ophthalmics | Strategic Sponsor

Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

SPO

NSO

R PR

OFI

LES

Page 67: OIS@AAO October 16th, 2014

67

SV Life Sciences | Founding Sponsor

SV Life Sciences is a global leader in healthcare investing. SVLS employs a diversified strategy within healthcare and generally targets early stage opportunities in biotechnology, a combination of early and expansion stage deals in medical devices and growth equity opportunities within the healthcare services and healthcare information technology segments.

www.svlsa.com

TearScience | Supporting Sponsor

TearScience® has pioneered ophthalmic procedures and devices that identify, diagnose and treat evaporative dry eye. The TearScience® in-office Dry Eye Solution includes the SPEED© Dry Eye Questionnaire, Korb MGE™, LipiView® Ocular Surface Interferometer and LipiFlow® treatment device along with a simplified implementation plan, practice marketing tools, and proven procedure support.

www.tearscience.com

Translatum Medicus | Supporting Sponsor

Translatum Medicus inc (TMi) de-risks and accelerates drug development for dry Age Related Macular Degeneration. TMi’s technologies include a pre-clinical model that mimics advanced dry AMD and aligns with clinical trial endpoints, and TMi-018, that dose-dependently protects against RPE loss. TMi-018 is safe in clinical studies for non-ophthalmic indications.

www.translatummedicus.com

Versant Ventures | Founding Sponsor

Versant Ventures is a leading venture capital firm specializing in investments in game-changing biopharmaceutical and medical device opportunities. Versant pioneered the build-to-buy structured exit model, creating new companies based on insights and knowledge. The experienced team of investors is committed to helping entrepreneurs build developing breakthrough therapies successful companies.

www.versantventures.com

WaveTec Vision Systems | Supporting Sponsor

WaveTec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons. Our revolutionary ORA System® provides intraoperative refractive information to ophthalmologists worldwide, allowing them to deliver the best possible vision for their cataract patients.

www.wavetecvision.com

SPON

SOR PRO

FILES

Page 68: OIS@AAO October 16th, 2014

68

WilmerHale | Supporting Sponsor

WilmerHale represents industry leaders in biotechnology, pharmaceuticals, medical devices and beyond in confronting and resolving challenges. From companies at all stages of growth to venture capitalists and investment banks, WilmerHale understands the business of our life sciences clients and the changing regulatory, competitive and consumer demands that the industry faces.

www.wilmerhale.com

XOMA | Supporting Sponsor

XOMA’s portfolio of innovative product candidates is the result of the Company’s focus on allosteric modulation, which offers opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program in non-infectious uveitis, and ongoing studies in other IL-1-mediated diseases.

www.xoma.com

SPO

NSO

R PR

OFI

LES

Translatum Medicus Inc (TMi) de-risks and accelerates drug development for dry Age Related Macular

Degeneration. TMi’s technologies include a pre-clinical model that mimics advanced dry AMD and aligns

with clinical trial endpoints, and TMi-018, that dose-dependently protects against RPE loss. TMi-018 is safe in

clinical studies for non-ophthalmic indications.

For more information regarding Translatum Medicus Inc, go to:

www.translatummedicus.com

Page 69: OIS@AAO October 16th, 2014

7TH ANNUAL

O

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation.

OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies.

WWW.OIS.NET/AAO2015

2014 Attendee Demographics

UNITING OVER800 LEADERS

in the Development of Ground-Breaking

Ophthalmic Technologies

LAS VEGAS, NV

NOVEMBER 12, 2015 35+30+20+10+55%

10%

30%

20%

35% Physicians

Finance/Investment

Industry/Corporate Executives

Private Ophthalmic Companies

Press/Media

Page 70: OIS@AAO October 16th, 2014

12 a p r i l 2 0 0 9

ph

oto

cr

ed

it

12 a p r i l 2 0 0 9

ph

oto

cr

ed

it

e y e n e t 55

BEAT THE CLOCK n Register Now to Avoid Standing in Line LaterAvoid the long lines at the Registration area in New Orleans. Go online now to register for the following meetings:• Subspecialty Day (Nov. 15-16),• the AAOE half-day coding meet-ings (Nov. 16), or• the Annual Meeting (Nov. 16-19).

Register by Oct. 2 to have your badge and registration materials mailed to you before the Annual Meet-ing.

From Oct. 3 to 23, you can still register online, but you will need to pick up your badge and other meeting materials onsite.

After Oct. 23, you must register at the Morial Convention Center. The Academy Plus course pass, most ticket prices, and Subspecialty Day fees in-crease onsite.

Register now. Go to www.aao.org/registration.

n Notify the Academy if You Need Special AssistanceThe Academy wishes to ensure that no individual with a disability is excluded or denied services, segregated, or oth-erwise treated differently from other individuals because of the absence of auxiliary aids or services. If you need any of the auxiliary ser-vices identified in the Americans With Disabilities Act, e-mail the Academy at [email protected].

PROGRAM

n Subspecialty Day: You Have Seven Meetings to ExploreSubspecialty Day opens on Friday, Nov. 15, with two meetings—Refrac-tive Surgery and Retina. It gets into full swing on Saturday, Nov. 16, with the addition of five more meetings—Cornea, Glaucoma, Neuro-Ophthal-mology, Oculofacial Plastic Surgery, and Pediatric Ophthalmology.

Explore all seven meetings. If you register for one of the Saturday-only meetings, you can attend any Subspe-

cialty Day session that takes place that day. If you register for a two-day meet-ing, you also can attend any session from either of Friday’s Subspecialty Day meetings.

n Program Directors Previewthe Peds and Retina MeetingsThis month, program directors for the Pediatric Ophthalmology and Retina Subspecialty Day meetings share some of this year’s highlights. To see the full schedules, go to www.aao.org/2013 and click “Subspecialty Day.”

(See July’s EyeNet at www.eyenet.

55 Beat the Clock

55 Program

n Make the Most of your tiMe in the exhibit hall. The Annual Meeting features the world’s largest exhibition of ophthalmic technology, products, and services—and you can use the Virtual Ex-hibition to zero in on those exhibitors that will be most useful to your practice.

use the Virtual exhibition to plan ahead. Go to www.aao.

Destination AAO 2014

57 Hall Highlights

g e t r e a d y f o r c h i c a g o : p a r t 1

screenshot of Online Pro-gram search, tk tk tk

screenshot of Online Pro-gram search, tk tk tk

org/2013 and select “Exhibi-tion” from the left navigation bar. Choose your search criteria to locate exhibi-tors by company name, booth number, product categories, or the ophthalmic subspecialty they relate to—or simply type a term into the search field—and the relevant exhibitors will be circled on the map (see screenshot). Next, click on an exhibitor to review its digital booth.

Create a “My expo” account. If you would like to print a personalized map of exhibitors, first visit the Virtual Exhibition and create a “My Expo” account by entering your e-mail address and choosing a password. Then you can tag the ex-hibitors you plan to visit and click “Print.”

AcademyExhibitorsTHE GUIDE TO

Exhibition Hall Map

FOLD-OUTCOVER

Best Practices in Patient Education18page

Why you should update your handouts.

An Insider’s Guide to Subspecialty Day4page

26 presentations you won’t want to miss.

22 EHR Exhibitors10page

Read this before visiting them.

FIRST EDITION WITH A FOCUS ON

FRIDAY & SATURDAY

THE CROSSROADS

ACADEMY LIVE Four daily e-newsletters with onsite reporting bring you the meeting’s clinical highlights.

GUIDE TO ACADEMY EXHIBITORS Comprehensive exhibitor listings, map, and contact information.

OCTOBER EYENET Part Six of Destination AAO 2014 gives a quick rundown of meeting essentials,plus a summary of what’s new this year.

ACADEMY NEWS A two-issue convention hall tabloid available Friday, Oct. 17, and Sunday, Oct. 19.

Meeting News with SoulEyeNet publications keep you in step

ICD-10: Get Up to Speed Fast16page

Use this at-a-glance resource.

Q&A With the Academy Laureate6page

How to become a successful pioneer.

Imaging Devices13page

Be DICOM-savvy when shopping.

SECOND EDITION WITH A FOCUS ONSUNDAY, MONDAY & TUESDAY

While in Chicago,

be sure to tune in to

’s meeting

publications. They

are instrumental to

staying informed

about meeting-related

news and events.

Visit us at the AAO 2014 Publishers’ Row and at www.eyenet.org.

THE CROSSROADSTHE CROSSROADSDON’T GET CAUGHT IN

Page 71: OIS@AAO October 16th, 2014
Page 72: OIS@AAO October 16th, 2014

“This is the glaucoma meeting to attend.”–George A. Cioffi, MD

Chairman of Ophthalmology, Columbia University of Physicians and Surgeons

REGISTER NOWwww.glaucoma360.org

February 6, 2015The Palace Hotel – San Francisco, CA

Speeding the development of new therapies and diagnostics for glaucoma patients

Keynote Speaker: Paul P. Lee, MD, JDChair of Ophthalmology and Visual Sciences; Director, W.K. Kellogg Eye Center,

University of Michigan

New HorizoNs Forum

251 Post Street, Suite 600, San Francisco, CA 94108 – (415) 986-3162 – www.glaucoma360.org

Page 73: OIS@AAO October 16th, 2014

4TH ANNUAL

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation.

OIS addresses key issues – both hurdles and opportunities while showcasing the most promising private ophthalmic companies.

WWW.OIS.NET/ASCRS2015

UNITING OVER400 LEADERS

in the Developmentof Ground-Breaking

Ophthalmic Technologies

SAN DIEGO, CA

APRIL 16, 2015

HILTON SAN DIEGO BAYFRONTPhysicians

Finance/Investment

Industry/Corporate Executives

Private Ophthalmic Companies

Press/Media

2014 Attendee Demographics25+25+30+10+1010%

10%

30% 25%

25%

Page 74: OIS@AAO October 16th, 2014

AG

END

A A

T-A-G

LAN

CE

AGENDA AT-A-GLANCE 6:30 - 7:30 AM Registration Check-in & Breakfast

12:41 PM Luncheon Commences

7:30 - 7:45 AM Welcome & Chairman’s Opening Remarks

1:10 - 1:35 PM Plenary Keynote: Accelerating Innovation In Ophthalmology

7:45 - 9:37 AM BioPharma Company Showcase

1:35 - 2:00 PM OIS Innovator Award Presentation

9:37 - 10:07 AM Networking Break

2:00 PM Luncheon Concludes

10:07 - 11:51 AM Device, Delivery & Diagnostics Company Showcase

2:00 - 2:07 PM Ophthalmic Innovation 2014 – “A View From The AAO”

2:50 - 3:20 PM Second Acts – Reinventing Your Company

4:10 - 4:40 PM IPOs In Ophthalmology – The Class Of 2014 & Beyond

11:51 - 12:21 PM Digital Ophthalmology Showcase

2:07 - 2:15 PM Ophthalmic Innovation 2014 – “A View From The NEI”

2:20 - 2:50 PM FDA Q&A

3:20 - 3:50 PM Afternoon Refreshment & Networking Break

4:00 - 4:10 PM A View Of The Public Sector & Exit Trends

4:40 - 5:10 PM Industry Consolidation: The Good, The Bad And The Unknown

5:10 - 6:30 PM Cocktail Reception

12:21 - 12:41 PM Digital Ophthalmology: The Alcon/Google Partnership & Beyond

2:15 - 2:20 PM Houston, We Have A Problem

3:50 - 4:00 PM Private Funding Trends Presentation

5:10 PM Wrap Up & Closing Comments


Recommended